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Abstract 
Introduction: Epilepsy is one of the commonest neurological disorders, affecting over 50 
million people worldwide.  Antiepileptic drugs (AEDs) are the mainstay of treatment, 
though they remain ineffective in 30% of individuals for whom they are prescribed.  
Pharmacoresistance in epilepsy is a significant problem. The mechanisms involved elude 
us still, with numerous theories and hypotheses posed in order to explain why this 
phenotype may exist. It is thought that genetic variation within certain genes may explain, 
at least in part, why the pharmacoresistant phenotype exists, and indeed may explain the 
dose-response variation observed in clinical practise.  
A genome-wide association study was conducted on newly-diagnosed patients with 
epilepsy upon starting their first AED, with the primary measure of outcome being one 
year remission of seizures at any time during follow-up. The strongest association was 
seen at a loci on chromosome 6, rs622902 (p=1.47×10
-7
) in the glutathione S-transferase 
alpha 4 (GSTA4) gene. GSTA4 is an enzyme of the glutathione-conjugating family of 
superenzymes that are responsible for a plethora of reactions that detoxify reactive 
metabolic intermediates, including many xenobiotics. In view of these findings, it was the 
aim of this study to explore the role of GSTA4 in newly-diagnosed epilepsy patients.  
Methods: Seventeen tagging SNPs representing 48 alleles across the GSTA4 gene were 
genotyped in 541 SANAD and 390 Glasgow patients using TaqMan quantitative PCR 
and Sequenom matrix-assisted laser desorption/ionisation time of flight mass 
spectrometry (MALDI-TOF MS). Binary logistic regression and Cox proportional 
hazards multiple regression analyses were conducted in order to analyse patient remission 
(yes/no) of epilepsy, and time to 12-month remission of epilepsy, respectively. Six 
clinical covariates were adjusted for in the analysis: age, sex, epilepsy type (partial, 
generalised, unclassifiable), number of pre-treatment seizures (2, 3, 4, 5, >5), AED 
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treatment (sodium valproate or gabapentin vs. neither) and EEG findings (normal, non-
specific, epileptiform, not-done).  
Results: Three SNPs (rs6904769, FDR = 0.0353; rs6922246, FDR = 0.0109 and 
rs384505, FDR = 0.0459) in the SANAD cohort showed an association with the binary 
outcome (yes/no) of seizure remission. Only rs6922246 (FDR = 0.0459) held association 
after combining both cohorts. 
Two SNPs (rs6904769, FDR = 0.0491 and rs6922246, FDR = 0.00380) were significantly 
associated with time to 12-month remission of epilepsy. This association held in 
rs6922246 (FDR = 0.0459) after combining the cohorts. 
Conclusion: Polymorphism in rs6922246 may be associated with both the remission of 
epilepsy and the time to 12-month remission of epilepsy. Validation in an independent 
cohort is necessary to explore this link further.  
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Chapter 1: Introduction 
1.1 Epilepsy 
As with many diseases - particularly those affecting the nervous system - epilepsy was 
considered a symptom of demonic possession. For epilepsy, this belief was held firmly 
until the period 1860-1910, when the supernatural explanation for the cause of epilepsy 
was lain to rest, and the modern era of scientific theory was initiated by the ‘father of 
epilepsy’, John Hughlings Jackson (1).  
Much like headache, epilepsy is a symptom of neurological dysfunction rather than a 
disease in itself per se (2). The distinction between a seizure and epilepsy is subtle, in that 
any person can have a seizure under certain pathological conditions such as 
hyponatraemia, hypoglycaemia, alcohol withdrawal, etc., whereas epilepsy is a condition 
of recurrent, unprovoked seizures whereby the known pathological conditions such as 
those aforementioned are absent. Therefore, every patient with epilepsy has seizures, but 
not ever patient with seizures has epilepsy. The underlying neurological pathology in 
epilepsy is manifest as spontaneous neuronal discharge of cerebral cortex neurons 
resulting in seizures. The epilepsy type is dependent on a variety of factors, though the 
anatomical location of the epileptogenic focus, along with any secondary generalisation, 
dictates the phenotype most strongly. 
The epilepsies comprise a group of disorders which are diagnosed following two or more 
spontaneous seizures for which no other precipitating factor may be attributable – that is, 
having ruled out cardiac, metabolic and other systemic causes for seizures. Thorough 
neurological assessment to include neuroimaging is necessitated in certain patient groups 
depending on the list of likely differential diagnoses, as seizures may be secondary to the 
presence of other central nervous system pathology (space occupying lesions), or may 
ensue following a ‘normal’ physiological reaction to fever – i.e., childhood febrile 
seizure. Care must be taken with the diagnosis, as its label is often commensurate with 
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negative connotations: quality of life is often greatly impacted, and stigma is something 
many patients with epilepsy often report. 
Quality of life in epilepsy is negatively impacted upon for several reasons. Unlike other 
chronic diseases, epilepsy may result in withdrawal of driving privileges, such that one 
must be seizure-free for 12 consecutive months in order to regain a licence from the Drive 
and Vehicle Licensing Agency (DVLA). A measurement of outcome in epilepsy research 
is time to 12-month remission, which ideally encompasses this restriction, also. 
Furthermore, the inability to predict the next seizure often leads to patients being cautious 
about being away from home, developing anxiety and becoming caught in a spiral of fear 
and emotion often resulting in depression as a concurrent diagnosis.  
A multitude of underlying factors are recognised as responsible for the causation of 
epilepsy, and it is now thought that the disease is multifactorial in most patients. The list 
of aetiologies is vast, and can range from underlying genetic factors through to structural 
cerebral pathology as in mesial temporal sclerosis. Sclerosis of the mesial temporal lobe 
structures is not considered to be primary causative, as it is not strictly known whether the 
sclerosis arises as a result of the epilepsy, or whether the sclerosis is a prerequisite to the 
epilepsy. This may be the case for other pathologies observed in patients with epilepsy. 
The mainstay of medical treatment is with antiepileptic drugs (AEDs). These drugs are 
successful in treating the epilepsy in around 70% of patients who take them, with the 
remaining 30% being considered pharmacoresistant (3, 4). Pharmacoresistance in 
epilepsy yields yet more problems for patients, as poorly-controlled seizures may result in 
significant morbidity during a loss of consciousness, or even mortality as in the sudden 
unexplained death in epilepsy (SUDEP).  
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1.1.1. Incidence and Prevalence  
Epilepsy is a common neurological condition affecting over 50 million people worldwide, 
and this figure is a likely gross underestimate (5). Unlike many chronic diseases, epilepsy 
is, for the most part, a hidden disorder, and is more widespread in society than is often 
thought. The incidence of epilepsy as cited in the literature varies significantly, though a 
large meta-analysis in 2011 by Ngugi et al (5) reported that the mean incidence was 50.4 
cases per 100,000 population per annum. This figure is higher for those living in 
developing nations (81.7 per 100,000 per year) and is also higher for those of lower 
socioeconomic status. The prevalence of the disorder is estimated at between 4 and 10 
persons per 1,000 (6). Increased prevalence of epilepsy in developing nations is most 
likely the result of poor maternal health, particularly in the first trimester during neural 
tube development, higher birth complications and subsequent neonatal anoxia, and poorer 
environmental conditions during the perinatal period (5, 6).  
The distribution of incidence against age for epilepsy is bimodal; the first peak is in the 
early years of life, and the second occurs in the elderly population. The latter probably 
occurs in accordance with a greater incidence of neurological dysfunction with advancing 
age, most notably cerebrovascular disease. In recent years, the incidence of epilepsy in 
the paediatric population has seen a decline, and this is thought to have occurred 
secondary to better maternal heath during pregnancy and increased standards of neonatal 
and perinatal care.  
 
1.1.2. Aetiology of epilepsy 
Unfortunately, the aetiologies of epilepsy, on the whole, are still poorly understood. As 
with many conditions, notions regarding causation have evolved over time in tandem with 
our scientific knowledge about the physiology of health and disease. This is particularly 
true for epilepsy. The advent of advanced neuroimaging, both computed tomography 
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(CT) and magnetic resonance imaging (MRI), along with significant advances in 
molecular biochemistry, have revolutionised epileptology, though there is still a long way 
to go. It is now possible to discern structural cortical abnormality from other causes of 
epilepsy, and many of the inherited errors of metabolism that lead to specific epilepsy 
syndromes are well understood (1). However, the vast majority of epilepsies still remain 
‘cryptogenic.’ Genetic predisposition is thought to contribute significantly, and recent 
advances in molecular genetics offer further light and promise to understanding the 
aetiology of epilepsy.    
 
1.1.3. Diagnosis 
The diagnosis of epilepsy is notoriously difficult. As such, it is a recommendation of the 
National Institute for Health and Clinical Excellence (NICE) that the diagnosis be 
confirmed by a specialist clinician with an interest in the condition (7).  
Whilst the majority of medical diagnoses can be made on history and examination, 
clinical investigations such as haematological, biochemical and/or imaging studies can 
often confirm or refute the diagnosis. This is often not the case with epilepsy. A thorough 
history of the seizure/s, including details of the events preceding and following the 
seizure, is vitally important. A collateral history from an eye-witness is also an invaluable 
part of the diagnostic process. Neuroimaging or neurophysiological testing may offer 
little additional information to the initial event, and clinical examination is often 
unremarkable. Once other causes have been ruled out, a diagnosis of epilepsy can be 
made following two or more unprovoked seizures, and only then do other studies such as 
electroencephalography (EEG) or neuroimaging become useful for confirmatory or 
classification purposes.  
18 
 
1.1.4. The classification of seizures and epilepsy 
Seizures are clinically classified into two main categories: partial/localised/focal and 
generalised. Where the seizure cannot be classified, it should be labelled ‘unclassifiable’ 
until such time as additional information becomes available enabling its inclusion in one 
of the two principal categories (8).  
This classification system is centred on the anatomical area of cortical discharge that 
manifests as a seizure. Partial seizures are those that occur with a discrete area of 
discharge that is attributable to a particular area of brain and that does not involve the 
entire cerebral hemispheres bilaterally. Generalised seizures involve all areas of the brain 
having spread via the deep brain structures/corpus callosum to involve both hemispheres. 
The focus in partial seizures is often easily discerned by the seizure itself; involvement of 
the motor strip will affect the contralateral limb(s), and activation of the reticular 
formation in the midbrain will lead to loss of consciousness, as in generalised seizures or 
complex partial seizures.  
Within these two broad categories, there are several subtypes that are based upon their 
clinical manifestations. The International League Against Epilepsy (ILAE) published two 
systems of classification: one regarding the classification of seizures, and the other on 
epilepsies. The seizure classification is outlined in a simplified manner in table 1.1 below, 
and the epilepsy classification is detailed thereafter. A detailed description of epilepsy 
subtypes and syndromes is beyond the scope of this short introduction.  
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Table 1.1. Simplified adaption from the 1981 ILAE classification of seizures(8).  
Classification of Seizure Seizure Type 
 
 
Generalised 
(consciousness impaired) 
Tonic-clonic 
Absence 
Myoclonic 
Tonic 
Clonic 
Atonic 
 
Partial 
Simple partial 
Complex partial (consciousness impaired) 
Partial with secondary generalisation (consciousness 
impaired) 
‘Unclassifiable’  
 
Below is the latest accepted classification of the epilepsies from the ILAE. 
1.Localization-related (local, focal, partial) epilepsies and syndromes 
1.1 Idiopathic (with age-related onset) 
Benign childhood epilepsy with centro-temporal spikes 
Childhood epilepsy with occipital paroxysms 
Primary reading epilepsy 
1.2 Symptomatic 
Chronic progressive epilepsia partialis continua 
Syndromes characterized by seizures with specific modes of precipitation 
Temporal lobe epilepsies  
Frontal lobe epilepsies  
Parietal lobe epilepsies  
Occipital lobe epilepsies 
1.3 Cryptogenic 
2. Generalized epilepsies and syndromes 
2.1 Idiopathic (with age-related onset) 
Benign neonatal familial convulsions 
Benign neonatal convulsions 
Benign myoclonic epilepsy in infancy 
20 
 
Childhood absence epilepsy 
Juvenile absence epilepsy 
Juvenile myoclonic epilepsy (impulsive petit mal, Janz syndrome) 
Epilepsy with grand mal seizures (GTCS) on awakening 
Other generalized idiopathic epilepsies 
Epilepsies with seizures precipitated by specific modes of activation 
2.2 Cryptogenic or symptomatic 
West syndrome (infantile spasms) 
Lennox-Gastaut syndrome 
Epilepsy with myoclonic-astatic seizures 
Epilepsy with myoclonic absences 
2.3 Symptomatic 
2.3.1 Non-specific aetiology 
Early myoclonic encephalopathy 
Early infantile epileptic encephalopathy with suppression bursts 
Other symptomatic generalized epilepsies 
2.3.2 Specific syndromes 
Epileptic seizures complicating other disease states 
 
1.1.5. Pharmacological treatment of epilepsy 
Pharmacological therapy remains the mainstay of epilepsy treatment. The ultimate goal of 
AED therapy is to achieve total seizure freedom whilst producing no side-effects from the 
medication. Seizure freedom with no side-effects is a scenario seldom seen by the 
clinician, and often a balance between seizure control and side-effects must be struck in 
order to obtain the best possible outcome for any given patient.   
Of patients treated with AEDs, approximately 70% will have their seizures well-
controlled, while the remaining 30% of patients are considered to have pharmacoresistant 
epilepsy and receive little (if any) benefit from drug therapy (3, 4).  
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The current market has over 20 AEDs available for prescription. Figure1.1 illustrates the 
main AEDs available today and their approximate year of approval for marketing. Even 
with the exponential increase in AEDs coming to market in recent decades, there has been 
no real revolution in the treatment of the condition (9). With approximately 50 million 
people worldwide suffering from epilepsy and 30% of those inadequately served by 
existing medication, pharmacoresistant epilepsy represents a significant global health 
issue.  
There is a clear need for the development of novel, more effective AEDs. However, this 
is unlikely to be achieved with any significant success until the mechanisms underpinning 
epileptogenesis are unravelled and new targets for drugs are discovered.  
 
 
 
Figure 1.1. AED development since 1900, showing the exponential rise in AED drugs 
coming to market in the past 20 years.                                                                                 
Taken from Arzimanoglou et al (9).  
 
22 
 
1.1.5.1. Choice of antiepileptic medication 
The choice of AED is a decision directed by guidelines published by NICE (7), which 
reflect evidence-based practise and the opinion and experience of specialist clinicians 
with an interest in epilepsy.  Several factors are considered in AED prescribing; foremost 
is the suitability of the drug for a specific seizure type or syndrome. Most AEDs are not 
suitable for all seizure/epilepsy types, and in some circumstances may even exacerbate 
the condition. The side-effect profile of the medication must also be borne in mind, with 
switching of AEDs commonplace owing to unacceptable side-effects. Further factors 
influencing choice include age, sex, concomitant medications, patient preference (usually 
on the basis of anticipated side effects), and cost. 
The current guidelines for AED selection published by NICE are summarised in table 1.2 
below. Specific epilepsy syndromes and status epilepticus are not included here. It is 
advised that monotherapy be used wherever possible, and that add-on therapy should not 
be attempted until all first-line agents have been trialled to their maximum tolerated dose. 
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Table 1.2: Utilisation of AEDs as recommended by NICE. Adapted from NICE (7).                                                
Seizure Type 1
st
-line AED Adjunctive AED Others 
 
Generalised tonic-
clonic 
Carbamazepine 
Lamotrigine 
Oxcarbazepine 
Sodium valproate 
Clobazam 
Lamotrigine 
Levetiracetam 
Sodium valproate 
Topiramate 
 
Tonic or atonic Sodium valproate Lamotrigine Rufinamide 
Topiramate 
 
 
Absence 
Ethosuxamide 
Lamotrigine 
Sodium valproate 
Ethosuxamide 
Lamotrigine 
Sodium valproate 
Clobazam 
Clonazepam 
Levetiracetam 
Topiramate 
Zonisamide 
 
Myoclonic 
Levetiracetam 
Sodium valproate 
Topiramate 
Levetiracetam 
Sodium valproate 
Topiramate 
Clobazam 
Clonazepam 
Piracetam 
Zonisamide 
 
 
 
Focal 
Carbamazepine 
Lamotrigine 
Levetiracetam 
Oxcarbazepine 
Sodium valproate 
Carbamazepine 
Clobazam 
Gabapentin 
Lamotrigine 
Levetiracetam 
Oxcarbazepine 
Sodium valproate 
Topiramate 
Eslicarbazepine 
acetate 
Lacosamide 
Phenobarbital 
Phenytoin 
Pregabalin 
Tiagabine 
Vigabatrin 
Zonisamide 
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Chapter 2: Early work, patient cohorts, and genome 
wide association study 
2.1. The SANAD cohort 
The standard and new antiepileptic drug (SANAD) study was an un-blinded, multicentre, 
randomised clinical trial designed to analyse which of the current standard and new 
antiepileptic drugs had superiority in both clinical and cost effectiveness in newly-
diagnosed patients with epilepsy. Over 2,400 patients were recruited into the trial, and 
were prospectively followed up for a period of at least 1 year from the initiation of their 
first AED (10, 11). Drug response phenotypes were reported by consulting the clinical 
trial database.  
A subset of the SANAD cohort was consented to provide a blood sample that was to be 
used for DNA extraction and later genetic analysis. The approval for this was given by 
the North-West multicentre research ethics committee in August 2002.  
2.2 The Glasgow cohort 
The Glasgow cohort comprises 285 newly-diagnosed patients with epilepsy that were 
recruited from the Western Infirmary, Glasgow. Drug response phenotypes in this study 
were identified retrospectively from prospectively-collected trial data and/or from 
hospital notes, thereby making the available clinical data more comprehensive than the 
SANAD data set. Patients were self-reported as having European ancestry and blood 
samples for DNA analysis were collected with consent following approval from the West 
ethics committee, North Glasgow University Hospitals NHS Trust in September 2002.  
2.3 The Melbourne cohort  
The Melbourne epilepsy pharmacogenetics cohort (hereafter designated the ‘AUS’ 
cohort) was a prospective study of the genetic influences on treatment outcomes in 
newly-diagnosed epilepsy patients. This cohort consisted of 115 patients, in which 4,041 
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SNPs in 279 candidate genes were used in order to try and determine which SNPs were 
most influential in predicting seizure control following 1 year of AED therapy using a k-
Nearest neighbour (kNN) model.  
 
2.4. Variation between the SANAD and Glasgow cohorts 
Differences between the cohorts that were of note include the geographical distribution of 
the patients in the SANAD cohort; these patients are representative of the UK with their 
diagnoses being made by clinicians nation-wide. Conversely, the Glasgow cohort was 
representative of a discrete geographical area with the diagnoses made by the same group 
of clinicians. Further, whilst the Glasgow data was deemed to be more comprehensive, 
data that was not available from this group included information regarding neurological 
deficit. The significance of these is discussed in the appropriate sections.  
 
2.5. Genome wide association study 
Genome wide association studies (GWASs) have revolutionised the experimental basis of 
how we study the genetics of human disease. This approach relies on data obtained by the 
International HapMap project, which is a multi-country effort to catalogue genetic 
similarities and differences within humans in order to better understand how genetics 
contributes to disease and variation in treatment responses with pharmaceutical agents. 
GWAS also takes advantage of the fact that variance within the genome at one particular 
locus can be used to predict variance at an adjacent locus. These probabilities remain high 
over distances of approximately 30,000 base pairs of DNA within the human genome, 
which enables the entire genome to be analysed for common variants by genotyping 
approximately 500,000 markers of the estimated 3-10 million polymorphisms believed to 
be present (12).  
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The results of a GWAS are typically illustrated in the form of a Manhattan plot, which 
displays statistical significance on the y-axis (as –log10 p-value) against chromosome 
number on the x-axis, for each genotyped SNP. Genome wide significance (GWS) is 
arbitrarily assumed at a p-value of <1x10
-4.5
 for discovery analysis and a p-value of 
<5x10
-8
for meta-analysis used in validation. Below GWS, the general consensus is that 
meta p-values in the interval 5x10
-8
 < p < 5x10
-7
 are suggestive of causal genomic 
association.   
A GWAS of treatment response in newly-diagnosed epilepsy patients was conducted on 
patients from the SANAD cohort at the Wellcome Trust Sanger Institute on an Illumina 
660Q GWAS chip (unpublished data). The aim of this was to identify regions of DNA 
that were highly polymorphic in order to begin to understand the role of SNP variations in 
the response to AED therapy. These data were meta-analysed with those from the AUS 
cohort for the purposes of validation. The primary outcome in this analysis was 1-year 
remission of seizures at any stage during follow-up, with a minimum follow-up of one 
year from initiation of AED therapy.  
The analysis was adjusted for clinical covariates (listed below) that were discovered to 
have a significant (p<0.05) influence on the trait of interest (i.e., likelihood of 1-year 
remission) following a univariate logistic regression of the SANAD data set. Validation 
analysis in the AUS cohort was also adjusted for these covariates, regardless of whether 
they were significantly associated with outcome in this cohort alone. 
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2.5.1 Clinical covariates included in the GWAS analysis 
The following is a list of the clinical covariates included in the GWAS analysis. 
- Age 
- Sex  
- Epilepsy type (generalised, partial or unclassified) 
- Treatment (sodium valproate, gabapentin or neither) 
- EEG (normal, abnormal or not done) 
- Neurological deficit (yes or no) 
- Number of pre-treatment seizures (2, 3, 4, 5 or >5) 
A total of 933 patients were included in the final meta-analysis. Of these, 671 were from 
the SANAD cohort (438 cases, 233 controls) and 262 from the AUS cohort (188 cases, 74 
controls).   
2.5.2. Results of the GWAS 
 
Figure 2.1. GWAS Manhattan plot illustrating the most significant loci of rs622902                 
(p = 1.47×10
-7
) in the GSTA4 gene region 
The Manhattan plot identified 3 loci with meta p-values <5×10
-7
 (this significance level is 
illustrated by the horizontal bar), suggestive of association between the likelihood of 1-
year remission and genetic variants in these genomic regions. Of these loci, the strongest 
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association was observed in chromosome 6; the most significant p-value (p=1.47×10
-7
, 
log10 value=6.83) was attributed to the SNP rs622902, located within the gene encoding 
glutathione-S-transferase alpha 4 (GSTA4). Other loci identified included a SNP on 
chromosome 2 which represents rs13022574 – the DPP10 gene, and rs37919 on 
chromosome 7 within the region of GNA1, CD36 and GNAT3. The former is a dipeptidyl 
peptidase-like protein that regulates the functional properties of neuronal Kv4 channels 
whose implication in epilepsy has been previously described by Maffie and Rudy (13). 
GNA1 is glucosamine-phosphate N-acetylytransferase; CD36 is a thrombospondin 
receptor; and GNAT3 is a a guanine nucleotide binding protein. The role of these SNPs 
on chromosome 7 is less obvious in epileptogenesis.  
An overview of GSTA4 is given in the next chapter commensurate with a hypothesis for 
its role in epileptogenesis and the pharmacoresistant phenotype.  
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Chapter 3: Glutathione and the glutathione S-
transferase enzyme superfamily 
3.1 Glutathione 
Glutathione (GSH) is a molecule of detrimental importance in the physiology of cellular 
redox balance where, via the action of glutathione S-transferase (GST) enzymes, it 
prevents the oxidation of cellular compounds, organelles and membrane lipids by toxic 
phase I metabolites. It was discovered by Nobel laureate Sir Frederick Gowland Hopkins 
of Cambridge University in 1922, where he noted that the addition of GSH could restore 
a tissues ability to reduce methylene blue, when that tissue had previously lost its 
reducing power (14).  
 
 
 
 
Figure 3.1. The structure of glutathione                                                                                      
Taken from Thomas J, 1999 (15).  
Figure 1.2 depicts the structural representation of GSH. It is a water soluble tripeptide 
antioxidant consisting of glycine, glutamate and cysteine. It is an important molecule, 
thought to maintain proteins in their reduced thiol state and therefore prevent cysteine 
residues from becoming oxidised and forming disulphide bonds with one another. Along 
with its role in the redox reactions of the cell; the role in leukotriene, steroid and 
prostaglandin synthesis; and its involvement in cell signalling, it has also been reported 
that GSH may have a part to play in the other basic cell functions such as apoptosis and 
regulation of the cell cycle (16).   
32 
 
Schafer and Buettner (17) have conducted extensive research into GSH. They have shown 
that the intracellular concentrations of GSH vary, with the distribution being somewhat 
compartmentalised. The highest concentration of GSH can be found in the cytoplasm – 
between 1 and 11mM – mirroring the fact that this is the site of GSH synthesis. The 
mitochondria also contain a separate pool, where the process of oxidative 
phosphorylation produces superoxide (O2
-
) that would otherwise destroy the organelle 
and cell (16, 18). Nuclear GSH maintains the redox state of important sulfhydryls that 
exists within proteins necessary for DNA repair (18). This compartmentalisation of GSH 
is important; radical species produced within the cells have a known short half-life, and 
their subsequent damage occurs close to the sites at which they are produced (16). In 
order for their effective removal, GSH must be present in these sites of radical 
manufacture such that the redox balance is maintained. 
The common affinity for GSH shown throughout the GST superfamily also illustrates the 
importance of this molecule as a powerful reducing agent. Whilst the GSTs have affinity 
for a multitude of substrates and compounds, this affinity shown throughout all members 
of the cytosolic and mitochondrial GST families for GSH specifically is owed to a GSH 
binding site in the GST macromolecule – the ‘G-site’ (19). This will be discussed in 
greater detail in section 1.2.3. 
The synthesis of GSH occurs de novo with the reduced form, GSH, found in much greater 
concentration than the oxidised form, glutathione disulphide (GSSH). Reduction of 
GSSH is by the enzyme glutathione reductase (20). The synthesis and degradation of 
GSH is linked with the γ-glutamyl cycle, which is depicted below in figure 1.3. 
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Figure 3.2. The synthesis and degradation of GSH within the γ-glutamyl cycle                                     
Taken from Masella R & Mazza G, 2009 (16). 
1)  γ-glutamylcysteine synthetase; 2) GSH synthetase; 3) γ-glutamyltranspeptidase; 
4) γ-glutamylcyclotransferase; 5) oxoprolinase. 
CYS-GLY – cysteinyl glycine; γ-GT – γ-glutamyl transferase 
 
3.2. The glutathione S-transferase family 
The Glutathione S-Transferases (GST), named thus owing to their ability to transfer a 
functional group from glutathione (GSH) to an acceptor species, comprises a group of 
ubiquitous enzymes vital to a plethora of organisms across many kingdoms and phyla 
(21).  Their role is varied, but ultimately they are involved in biochemical reactions that 
catalyse nucleophylic attack by GSH in the reduced state on non-polar compounds 
containing an electrophylic carbon, nitrogen, or sulphur atom (19, 22). Such catalysis is 
detrimental to the function and survival of the cell, as conjugation of GSH with reactive 
electrophylic intermediates yields compounds that are both less reactive and more soluble 
(19). Many of the reactive intermediates are by-products of phase I oxidative metabolism 
and other in vivo biochemical reactions (19, 22, 23). However, GSTs astounding affinity 
for a multitude of substrates enables this group of enzymes to catalyse many xenobiotics 
and environmental hazardous substances including pesticides, carcinogens, and several 
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pharmacological agents, and are thereby considered a highly sophisticated evolutionary 
mechanism for removing cytotoxic agents from within the cell. Further research has also 
elucidated many other roles, including hormone synthesis, tyrosine degradation, and 
peroxide breakdown (22). Not only are GSTs involved in enzymatic reactions involving 
GSH, but they have also been shown to synthesise leukotrienes via mechanisms which 
utilise GSH as a co-factor, and they are also implicated in the production of 
prostaglandins (22). These will be discussed in greater detail in the relevant sections. 
There exist three superfamilies of GST: cytosolic, mitochondrial, and MAPEG 
(membrane-associated proteins in eicasanoid and glutathione metabolism), the latter 
formerly designated microsomal GST (MGST). Both cytosolic and mitochondrial 
subtypes share deep evolutionary similarities in their three-dimensional structure, but 
these groups bear no reflection of a common ancestry with the MAPEG enzymes; 
cytosolic and mitochondrial GSTs form dimers, where MAPEG GSTs form bound 
trimeric enzymes. Cytosolic GSTs comprise the largest group, and are responsible for the 
catalysis of the greatest variation of biochemical reactions within the cell. It is, therefore, 
the group that will be elaborated upon in greatest detail. 
As aforementioned, GSTs are also implicated in the detoxification of xenobiotics, and as 
such these groups of enzymes are of great interest to both pharmacologists and 
toxicologists. As we learn more regarding the structure, function, and genetics of these 
enzymes, interest within them from a clinical perspective grows exponentially. GST is 
involved in the metabolism and detoxification of a multitude of chemotherapeutic agents, 
with upregulation of these enzymes being found in cancer cells, and henceforth leading to 
chemotherapeutic resistance (24). Further, their role in leukotriene synthesis has led to a 
wave of research activity into a target in asthmatic patients, where upregulation of 
leukotrienes are implicated in bronchiolar constriction. Drugs that antagonise the 
leukotriene molecules, such as montelukast, are now prescribed.   
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3.2.1. Nomenclature of the glutathione S-transferases 
An internationally accepted method for naming GST was long sought, in part due to the 
continually evolving knowledge of the function, and diversity, of these enzymes. Upon 
their initial discovery, GST was known to catalyse the reactions of GSH with 
bromosulfophthalein (25) and chloronitrobenzenes (26), and subsequently the name GSH 
S-aryltransferase was given. Other known GSTs involved in the catalysis of epoxides and 
alkyl halides were given the respective names GSH S-epoxide transferase and GSH S-
alkyl transferase (27). However, it was soon discovered that the compound 1-chloro-2,4-
dinitrobenzene acted as a ‘general’ substrate for all GSTs (28), and the original 
nomenclature had to be abandoned.  
 
There still exists debate in the naming of GSTs across the entire superfamily of enzymes. 
Decades of research into GST has procured much information on their importance in 
cellular homeostasis and detoxification of endogenous and xenobiotic compounds, and 
has thus necessitated a unified nomenclature method. To date, a system of internationally 
accepted nomenclature exists for the soluble mammalian GSTs, which includes cytosolic 
and mitochondrial enzymes (the latter of which are also designated GSTK).  
The nomenclature of the GSTs is based solely upon amino acid sequence similarity. 
Enzymes related more closely to others, based on their sequence, are further divided into 
classes which are identified by the use of the Greek letters: alpha, pi, mu, omega, etc (29). 
It should be noted that these are abbreviated using the Roman capitals: A, P, M, O, etc, 
and not their Greek symbols. Among members of the same cytosolic GST class, greater 
than 40% of the amino acid sequence is identical, whereas less than 25% of the sequence 
is shared between classes (19, 30). Within a given class, the subunit sequences are given 
Arabic numerals. When writing the gene encoding a particular GST, italics are used; 
conversely, when referring to the protein, italics are not used. For example, the gene 
encoding the pi class GST with subunit 1 is written GSTP1. As GSTs are dimeric, they 
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may be homodimeric composed of two copies of subunit 1, or heterodimeric (within the 
same class), composed of more than 1 subunit. In this case, the homodimeric protein 
Alpha would be written GSTA1-1; the heterodimeric protein alpha is written GSTA1-2. 
Similarly, the gene encoding GST class mu subunit 1 is written GSTM1, with the 
homodimeric protein written GSTM1-1. In cases where GSTs belonging to different 
biological organisms need to be distinguished, a lowercase prefix may be used to denote 
that species, such as r or p for rat and pig, respectively. In this case, the protein mu class 
GST with subunit 1 for each would be rGSTM1-1 and pGSTM1-1, respectively.   
 
3.2.2. Basic structural features of the glutathione S-transferases 
The first determined structure of any GST was that of the porcine pi subclass, pGSTP1-1, 
as described by Reinemer et al (31). Since then, the three dimensional structures of many 
of the other families and classes of GST have been elucidated by x-ray crystallography, 
including similarities and differences between their protein folding, and the chemical 
properties by which they interact with their substrates.  
 
Variation exists in the tertiary structure between each of the GST superfamilies and 
subsequent subclasses; as such, a detailed, intricate analysis of each individual structure is 
beyond the scope of this text. However, the common structural feature of the GSTs 
includes an N-terminal thioredoxin-like domain with a C-terminal domain composed of 
α-helices (19). The sites of binding for GSH and the electrophilic reactive species are 
denoted the ‘G-site’ and ‘H-site’, respectively (19, 32, 33). The G-site of the dimer 
enzymes is located within a cleft between the N-terminal of one subunit and the C-
terminal domain of the other, and this site is therefore completed only following the 
dimerisation of the two (32). The N-terminal domain comprises the majority of the G-site, 
whose topology, along with the H-site, is conserved surprisingly across all GST enzymes 
(33). The G-site is composed of four β-sheets with 3 adjacent α-helices (‘thioredoxin-
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like’) (34), while the H-site is constructed of the C-terminal domain, itself α-helical with 
a contributing loop from the N-terminal domain. Substrate specificity within the H-site is 
owed to variation in the amino acid sequence at this location (33).   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  The general crystallographic structure of GST illustrating the C- and N-
terminus and the common GST binding site for GSH.                                                          
Taken from Protein Data Bank: 
http://www.rcsb.org/pdb/explore/explore.do?structureId=1R5A                                        
 
3.2.3. The cytosolic glutathione S-transferases 
Cytosolic GSTs are dimeric proteins with between 199-244 amino acids (22). In 
mammals, there are seven subclasses: alpha (A), mu (M), pi (P), sigma (S), theta (T), 
omega (O) and zeta (Z). Other subclasses do exist (beta, delta, epsilon, lambda, phi, tau, 
and “U”) (22), though these enzymes are found in non-mammalian species and are not 
discussed further. 
 
The cytosolic GSTs, besides conjugating reactive species with GSH, are also involved in 
the intracellular transport mechanisms for the elimination of compounds from within the 
cell, binding ligands in a non-substrate manner (35). Such compounds include hormones, 
haem, bilirubin, and steroids, and it was this property that led to their initial name of 
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Ligandin (35) - this name was changed upon the discovery of the wide functional roles of 
these enzymes.  
 
The sigma class GST, otherwise known as haematopoeitic prostaglandin D synthase, 
converts PGH2 into PGD2 in a GSH-dependant manner, as outlined in figure 1.5 (36).  
The theta class GSTs are amongst the least studied of all mammalian GST isoenzymes, in 
part owing to the fact that they have a reduced affinity for the classical substrate 1-chloro-
2,4-dinitrobenzene compared with the other classes (37). Work carried out on the theta 
class has shown a sulphate-binding active site, which has proposed the hypothesis that 
these isoenzymes are important in reactions involving sulphate esters and, as such, may 
be important in the prevention of hepatocellular carcinoma (38, 39). Omega GSTs share 
common properties with the glutaredoxins, where these enzymes possess a cysteine 
within their active site and are thus able to form disulphide bonds with GSH and catalyse 
reductase reactions (40).  Both classes mu and pi GST have reported activities that inhibit 
apoptosis signal-regulating kinase 1 (Ask1) and c-Jun N-terminal kinases (JNK): Ask1 is 
vital to the mechanisms concerned with cytokine- and stress-induced apoptosis, and its 
inhibition by these GSTs during non-stressed conditions prevents premature and 
unnecessary apoptosis (41). JNK, a kinase involved with apoptosis following 
inflammation, heat shock, UV irradiation and cytokine presence, is particularly inhibited 
by GST pi, thereby also preventing unnecessary apoptosis (42, 43). Zeta GST, also 
known as maleylacetoacetate isomerase (MAAI), utilises GSH as a co-factor for the 
isomerisation reaction of maleylacetoacetate to fumarylacetoacetate (19). This 
isomerisation is critically important in the metabolism of both phenylalanine and tyrosine 
(19). Further, GSTZ GSTs is also implicated in reactions involving oxygenation, 
dehalogenation, and peroxidation, and also exhibits transferase activity - important 
metabolic clinical syndromes result with enzyme deficiencies of the tyrosine pathway, 
including phenylketonuria (19). Finally, the alpha class GST is important in the 
metabolism of a number of environmental carcinogens, including the ubiquitous 
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polyaromatic hydrocarbons (PAH), and they show particular affinity towards the 
metabolites of lipid peroxidation (44) and cell membrane oxidation (45).  
 
3.2.4. The mitochondrial glutathione S-transferases 
Mitochondrial GSTs, also known as GST kappa (GSTK), share deep structural 
evolutionary links with the cytosolic group of enzymes (46). They were first isolated 
from the mitochondria of rat liver by Harris et al (46) and this organelle-specific 
localisation was confirmed using immunohistochemical techniques by Thomson et al (47) 
on specimens of liver and kidney. A number of research methodologies by several groups 
has confirmed the presence of this class of GST in the mitochondria, as well as finding 
the enzyme within cellular peroxisomes where they act as peroxidase enzymes protecting 
against lipid-peroxides (30). The specific localisation of this class reflects the fact that 
GSTK is highly involved in the detoxification of reactive-oxygen species from the 
respiratory chain reactions and oxidative phosphorylation, particularly more so than other 
classes (48).  
 
Recently, research undertaken by Liu et al (49) has defined a role for GSTK as an 
adiponectin-interacting protein. Adiponectin is an adipokine molecule secreted 
specifically from adipose tissues where it is implicated in the metabolism of both glucose 
and insulin within insulin-sensitive tissues (50). Several compounds have been shown to 
be involved in the folding of these adiponectin molecules in the human body, by assisting 
in the formation of disulphide bonds. Interestingly, it was found by Liu et al (49) that 
increasing the concentration of GSTK directly correlated with an increase in 
multimerization of adiponectin by the formation of disulphide bonds, with the converse 
being true with a decrease in GSTK – this has led to the suggestion that GSTK may be 
concerned with the correct folding of these important metabolic proteins, and as such 
expression differences may carry a clinical implication in obesity disorders (51).  
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3.2.5. Membrane-associated proteins in eicosanoid and glutathione 
metabolism 
The MAPEG series of GSTs contains four subtypes (I-IV), of which there exist six 
isoenzymes belonging to subtypes I, II and IV in humans. These six isoenzymes are (52):  
1) 5-lipooxygenase activating protein (FLAP); 
2) Leukotriene (LT) C4 synthase (LTC4S); 
3) Microsomal glutathione S-transferase 1 (MGST 1); 
4) Microsomal glutathione S-transferase 2 (MGST 2); 
5) Microsomal glutathione S-transferase 3 (MGST 3), and; 
6) Prostaglandin E synthase (PGES). 
 
The initial two isoenzymes are involved in the biosynthesis of leukotrienes; LTC4S 
conjugates leukotriene A4 with GSH, and FLAP is necessary for the production of 5-
lipooxygenase from its precursor arachidonic acid. MGSTs 1-3 are GSTs as well as GSH-
dependent peroxidases; MGST 1 is implicated in the biochemical reactions conjugating 
electrophilic compounds with GSH, whilst MGST 2 and 3 both catalyse the conjugation 
of GSH with leukotriene A4.  Prostaglandin E synthase is involved in the biosynthesis of 
prostaglandin E2 (PGE2) from the precursor molecule prostaglandin H2 (PGH2), 
ultimately responsible for the synthesis of prostaglandin F2 (PGF2) - all of these  
biomolecules are potent mediators of inflammation (53). Figure 1.5 illustrates the 
synthesis of the eicosanoids. 
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Figure 3.4. The synthesis of the eicosanoids, with the specific role of GSH and GST shown 
in leukotriene (leukotriene C4) production                                                                   
Taken from: http://www.scienceofhealthindex.com/images/Eicosanoid_synthesis.jpg 
 
According to subdivision based on sequence, group I MAPEGs contain FLAP, LTC4S 
and MGST 2; group II contains MGST 3 as its only member; and group IV contains 
PGES and MGST 1. Group III subtypes are found only in the bacteria Escherichia coli 
and Vibrio cholera (22).  
 
Table 3.1. MAPEG subgroup with corresponding isoenzymes and their biological roles 
Subgroup Isoenzyme Biological Function 
 
 
I 
5-lipoxygenase activating 
protein (FLAP) 
Leukotriene biosynthesis 
activation 
Leukotriene C4 Synthase 
(LC4S) 
GST specific for LTC4 
synthesis 
Microsomal Glutathione S-
Transferase 2 (MGST 2) 
GST activity & GSH 
peroxidase activity 
II Microsomal Glutathione S-
Transferase 3 (MSGT 3) 
GST activity & GSH 
peroxidase activity 
 
IV 
Prostaglandin E Synthase 
(PGES) 
PGH2  PGE2 
Microsomal Glutathione S-
Transferase 1 
GST activity & GSH 
peroxidase activity 
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3.2.6. Variation within the roles of the cytosolic glutathione S-
transferases 
A brief overview of variation amongst the human cytosolic GSTs is given below in order 
to outline their varying roles within the human body, and to give an appreciation of what 
genetic variants/polymorphisms may have on their function.  
For reference, the cytosolic GSTs with their corresponding gene(s) and chromosome 
number are given below in table 1.4.  
Table 3.2. Cytosolic GSTs with known gene(s) and chromosomal number. 
 
3.2.6.1. Alpha Class 
Five GST alphas have been identified to date – GSTA1, A2, A3, A4 and A5 - all located 
on chromosome 6 (33, 54-56). Using gene-specific probes and real-time PCR methods in 
24 human tissue samples,  Morel et al (54) showed that GSTA1, GSTA2 and GSTA4 
were distributed widely in human tissues, whilst GSTA3 was somewhat rarer and GSTA5 
mRNA was not detected. Specifically, transcripts of GSTA4 were detected in all tissues, 
which was a finding echoed by Desmots et al (57) who found GSTA4 in all tissues by 
Northern blot analysis. GSTA1 and GSTA2 mRNA were often co-expressed.  GSTA3 
was found in several of the samples, though in high concentrations in lung, stomach, 
testis, placenta and suprarenal tissue. In all of the samples analysed, no transcript 
corresponding to the GSTA5 sequence was detected. 
GSTA1 has been implicated in the pathophysiology of inflammation, with its 
downregulation having profound implications for the mechanisms that guard against 
GST Class Known Gene(s)              Chromosome 
Alpha GSTA1-5 6 
Mu GSTM1-5 1 
Pi GSTP 11 
Zeta GSTZ 14 
Omega GSTO1-2 10 
Theta GSTT1-2 22 
Sigma GSTS 4 
43 
 
cellular stress from by-products of lipid peroxidation. Ng et al (58) showed that 
interleukin (IL)-1β, via a mechanism that involved the overexpression of a variant of 
hepatic nuclear factor 1 (HNF-1), caused the repression of GSTA1 during the 
inflammatory process. This indicates that GSTA1 may play an important role in the 
cellular mechanisms that protect against inflammation secondary to the by-products of 
lipid peroxidation.   
The GSTA2 protein is 222 amino acids in length with a molecular mass of 25,425. Its 
role in health and disease has been studied by several groups; GSTA2 is the known 
enzyme for conjugation of the myelosuppresive agent busulfan with GSH. This agent 
may be administered to patients undergoing haematopoietic stem cell transplantation 
prior to therapy, and its biotransformation appears unaltered by polymorphic variation 
suggestive of there being no consequence of base variation in these alleles (59). Board 
and Webb (55) also suggested that this particular GST may be implicated in the aetiology 
of non-haemolytic unconjugated hyperbilirubinaemia, indicating GSTA2 may have a role 
in the transport of compounds such as haeme and bilirubin.  
GSTA3 is a rarer subclass of the GST alphas and was discovered by Morel et al (54) in 
their experiments to be a rare message owing to splicing defects. The same group found 
that the gene contains 7 exons. Ilic et al (60) showed that GSTA3 knock-out mice were 
particularly sensitive to the cytotoxic effects of aflatoxin B1, whose role is well described 
in the pathogenesis of hepatocellular carcinoma. The enzyme also has a known role in the 
biosynthesis of a number of steroids, where it is implicated in the double-bond 
isomerisation of these molecules (61). It is a rare transcript (62), found largely in tissues 
where steroid synthesis is high – the ovaries, testes, placenta and adrenals (61). 
Polymorphism within the GSTA3 gene, therefore, may contribute somewhat to the 
pathology within steroid-producing tissue, though this link has not been investigated to 
date. 
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GSTA4 has a wide tissue distribution in humans. Amongst other organs, it is found 
within kidney, liver, brain, skin, heart and colon (63). This particular alpha isoform was 
isolated and cloned from a human cDNA library (62), whereupon it was shown to have 
particular enzymatic activity towards carbonyl compounds and reactive radical species 
(63), indicating a significant role for this isoform in cellular homeostasis. The role of 
GSTA4 will be discussed in further detail at the end of this section. 
To date, little is known regarding the role of GSTA5. Hayes et al (64) reported the 
upregulation of GSTA5 in rat hepatocytes following the administration of 
chemotherapeutic agents, with further computer modelling of the promoter region of 
GSTA5 identifying a possible antioxidant response element that may confer this resistance 
(64, 65). The postulated role of this enzyme in chemoresistance suggests their 
upregulation may also play a role in other diseases where pharmacoresistance is a 
problem, though this hypothesis has yet to be explored. 
3.2.6.2. Mu class 
The five known GST mu genes, GSTM1-5, have been mapped to chromosome 1 using 
locus-specific PCR primer pairs on DNA samples retrieved from human/hamster somatic 
cell hybrids (66). Of the GSTM subclass, both GSTM1 and GSTM2 have been shown to 
be the most active GSTs within the liver (67). The specific roles of these isozymes within 
the hepatic parenchyma, however, are poorly understood.  
Homozygosity for the GSTM1 null allele has been linked with carcinomas of the head and 
neck as discovered by Lohmueller et al (68) in a large metanalysis of 301 published 
genetic association studies. Another study by Huang et al (69) initially identified a 
statistical association between the SNP rs366631 and GSTM1 expression using GWAS. 
This SNP is found approximately 11kb downstream of the GSTM1 gene in the 3’ region. 
Later, the association was found to be invalid, and the false genotyping call arose from 
sequence homology and a GSTM1 region deletion. Following their work, the group 
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concluded that rs366631 is a pseudo-SNP and may, perhaps, be used as a biomarker for 
GSTM1 gene deletion. GSTM1 null has been implicated in several disease states, and its 
role in epilepsy is discussed further at the end of this chapter. 
In comparison to GSTM1, much less is known regarding the function of GSTM2, M3, 
M4 and M5. GSTM2 is a dimeric enzyme that is found mainly within liver and muscle 
tissues, and GSTM3 is found largely within the brain (70). Studies into the significance of 
GSTM4 gene variation in human disease are few, though one group suggested that a 
T2517C polymorphism within intron 6 of the GSTM4 gene is associated with carcinoma 
of the lung (Fisher’s Exact Test, p=0.026) in a population containing 136 lung cancer 
patients and 156 healthy controls (71).  
GSTM5 was discovered by Takahashi et al (72) by screening a human frontal cortex 
cDNA library with a rat cDNA that cross-hybridised with other human and rodent GSTM 
cDNAs. This isozyme was found to be expressed primarily in brain and lung tissue by 
Northern blot analysis, and is predicted to contain 217 amino acids. The role of GSTM5 
has yet to be outlined.  
3.2.6.3. Omega class 
Two members of the omega class are known to exist to date, whose loci exist on 
chromosome 10: GSTO1 and GSTO2 (40, 73).  Whilst all of the GST isozymes share 
structural and functional variance, the GST omega is somewhat further distinct from the 
others (33).  
GSTO1 cDNA was discovered by searching an expressed sequence tag (EST) database 
for homologies with GSTZ1. It is most closely related to GST zeta and contains 241 
amino acids (40). Whitbread et al (73) illustrated the ability of GTSO1 to reduce 
monomethylarsonic acid to monomethylarsonous acid, which is the rate-limiting step in 
the metabolism of inorganic arsenic. This class of GST possesses a 19 residue N-terminal 
extension forming a novel structural unit whose function remains elusive, and that is not 
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seen within any other class of GST. Further, substrates that are biochemically altered by 
other GSTs are not altered by certain GSTO1 alleles, and its ability to metabolise 
dehydroascorbate in a GSH-dependant reduction shows that this particular allele 
illustrates behaviour that is characteristic of the glutaredoxins rather than the GSTs (40, 
74). 
The role of GSTO2 currently remains unclear. Significant expression was found in the 
testes, though amounts have also been shown in kidney, liver, striated muscle and 
prostate tissues (73). This allele shares 64% of its amino acid sequence with GSTO1 (73).  
3.2.6.4. Pi class 
One member of the GST pi is currently known to date, and is coded by a loci found on 
chromosome 11 (33). Its expression can be found in all tissues of the human body, expect 
for red blood corpuscles and little amounts found in the liver (70, 75).  
GSTP was isolated by Kano et al (76) by screening a human placental cDNA library with  
rat placental GST cDNA. The protein is approximately 209 amino acids in length, and 
contains 7 exons which span approximately 2.8kb (77).  
Several studies have suggested a role for GSTP in a number of biochemical pathways, 
and its role in several disease states has been implicated. Expression of GSTP was found 
to be increased in many tumours relative to normal tissue samples, suggesting a role for 
GSTP in carcinogenesis (78). These links are poorly explored. 
A role in hepatotoxicity following overdose of paracetomol has also been outlined in 
experiments using GSTP. Mice null for GSTP were examined for the metabolic effects of 
this genotype, and it was discovered that these mice were highly resistant to the effects of 
the toxic paracetomol metabolite, NAPQI (79). The results of this analysis suggest that 
variation in GSTP may contribute to the toxicity following overdose of paracetomol.  
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Much interest in the polymorphism within GSTP has been shown. Of particular interest 
was a study conducted by Menegon et al (80), who pursued the widely-accepted 
hypothesis that Parkinson’s disease could be caused by numerous environmental factors, 
including xenobiotic agents and pesticides. Given the role of GST in the reduction of such 
compounds, and its presence in the blood-brain barrier (81), the group investigated the 
role of GST polymorphisms in the development of Parkinson’s disease in 95 patients and 
95 controls by PCR genotyping. When analysing the results of those patients who had 
reported pesticide exposure, associations were seen only within GSTP, with differences 
secondary to an excess of heterozygotes and non-carries of the A allele in the patient 
group compared to the control group.  
3.2.6.5. Theta class 
Two isozymes comprise the GST theta class (GSTT1 and GSTT2), whose location on 
chromosome 22 was found by in-situ hybridisation studies (82). Pemble et al (83) are 
responsible for the cDNA cloning of this class, and deduced its composition of 239 amino 
acids, though for some time GSTT was overlooked owing to its low activity with the 
classic GST substrate, 1-chloro-2,4-dinitrobenzene.   
A study by Chen et al (84) compared the frequency of the GSTT1 null genotype in 96 
myelodysplastic syndromes and 201 healthy controls matched for age, race and sex. 
Forty-six per cent of patients with myelodysplastic syndrome were null for GSTT1 
compared with 16% of controls. The results illustrated a 4.3-fold increased likelihood of 
myelodysplastic syndrome, though the mechanism of this increased inference was not 
understood.  
GSTT2 contains 244 amino acids and has a 55% sequence identity to GSTT1 (85). Little 
is understood regarding the role of this isozyme, though it has been suggested that SNPs 
in the promoter region of this gene (-537G>A, -277T>C and -158G>A) may confer 
greater risk of colorectal cancer (86).  
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3.2.6.6. Zeta class 
GST zeta was discovered using sequence alignment and phylogenetic analysis, and is 
located on chromosome 14 (87, 88).  This isoenzyme is found in abundance in the liver 
and proximal convoluted tubules of the kidney, where they catalyse GSH-dependant 
reactions involving an array of electrophilic alpha-halogenated acids (33). GST zeta is 
also characterised as maleylacetoacetate isomerase owing to its role in the catabolic 
pathway of both phenylalanine and tyrosine (89).  
Polymorphisms within GSTZ are known to have clinical consequence. Decreased ability 
to catalyse the aforementioned reactions lead to metabolic diseases including type I 
tyrosinaemia and phenylketonuria (90).  
3.2.7. An overview of glutathione S-transferase alpha 4 
Board et al (62) was responsible for isolating the entire GSTA4 cDNA clone from a 
human adult brain cDNA library. The protein is 222 amino acid molecules long with a 
molecular mass of 25.7kD. It shares 52% sequence identity with GSTA1, spans 18kb, and 
contains 7 exons. 
Within the GSTA4 gene region there are, to date, a total of 361 known SNPs (contig label: 
GRCh37.p5) including the intronic regions. Of these, 12 are known functional SNPs 
(non-synonymous). Fourteen exist in the 3’ UTR region and 5 are within the 5’ UTR 
region of the gene. The chromosomal coordinates are 6p12.1 and it can be found within 
base pairs 52,842,746 – 52,860,178 (91).  
The GSTA4 enzyme has been shown to have two specific functions. The enzyme shows a 
high affinity for 4-hydroxynonenal (4-HNE), a metabolic by-product of peroxide 
degradation from lipid membranes and arachidonic acid (92). At times of increased 
cellular damage, inflammation and metabolic stress, levels of 4-HNE rise as a result of 
peroxide degradation, and it is therefore thought that the role of GSTA4 in preventing this 
damage is important. Secondly, Board (62) showed that GSTA4 shows high affinity for 
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the catalysis of reactive carbonyl compounds such as alk-2-enals whose presence also 
lead to cellular stress and damage. Combined, the role of GSTA4 as a protector against 
reactive intermediates is considerable.   
A number of studies have been conducted into the link between GSTA4 and disease. It is 
known that insulin resistance is linked to an increase in the production of free radical 
species, resulting in the increased production of lipid aldehydes (93). These aldehydes are 
enzymatically degraded primarily by GSTA4. Decreased levels of GSTA4 and resultant 
increases in lipid aldehyde production were shown to cause abnormal protein 
carbonylation within adipocytes. The effect was aberrant glucose transport, lipolysis and 
mitochondrial respiration. Downregulation of GSTA4 may, therefore, contribute to the 
pathogenesis of insulin resistance and type 2 diabetes. Its role in other diseases may also 
be significant.  
Polymorphisms within GSTA4 have been associated with carcinoma of the lung. A 
genetic study in a Southeastern Chinese cohort by Qian et al (94) genotyped 3 SNPs 
(rs182623 – 1718:T>A, rs3798804 + 5034:G>A and rs316141 + 13984: C>T) in 500 lung 
cancer patients and 517 healthy controls. A significant association was observed in 
genotype and allele frequency distributions in -1718 between cases and controls (p=0.006 
and p=0.003, respectively). When comparing with the -1718TT genotype, those 
participants with the TA and AA genotypes were at a decreased risk of developing 
carcinoma of the lung (OR 0.63, 95% CI: 0.47 – 0.84, p=0.006).  
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3.2.8. The glutathione S-transferases and their role in epilepsy and 
antiepileptic drugs: Current literature 
The literature regarding the role of GSTs in epilepsy and its treatment is scarce, with very 
few published studies. There are, however, a small number of groups that have explored 
the role of certain cytosolic GST subclasses in epilepsy, or in their effect on AEDs.  
Liu and Tsai (95) studied the effects of the null genotype GST Mu (GSTM1(-)) in a 
cohort of 1323 patients; 97 patients with epilepsy with good seizure control on 
anticonvulsant therapy, 35 patients with intractable seizures on anticonvulsant 
polytherapy, and 1191 healthy control subjects. Good seizure control was defined as 
fewer than 2 seizures a month with monotherapy, and intractable seizures were defined as 
a seizure frequency of greater than 4 per a month whilst taking a combination of 
anticonvulsants with effective monitoring of blood levels for at least four months. 
Patients with generalised tonic-clonic seizures or secondary generalised tonic-clonic 
seizures were included in the study, and the pharmaceutical agents prescribed, either 
alone or in combination, included phenytoin, carbamazepine, valproic acid, and 
phenobarbital. Both null genotype of GSTM1 and the plasma level of malondialdehyde 
(MDA) were determined for the groups of patients outlined above. MDA is a marker of 
oxidative stress, and was used to indirectly measure the level of lipid peroxidation in the 
patients. The results showed that the allele frequency of GSTM1(-) genotype of the 
patients with intractable epilepsy was significantly higher than those with well-controlled 
epilepsy (80% vs. 48.5%, OR = 4.3, p = 0.001) and healthy controls (80% vs. 49.5%, OR 
= 4.1, p = 0.001). It was therefore suggested that the null Mu genotype may be a 
significant genetic factor that contributes to the highly variable response to anticonvulsant 
therapy observed in clinical practise.  
The GSTM1(-) genotype was also the topic of research, along with the GST theta null 
genotype (GSTT1(-)), for the hypothesis that either of these genotypes alone, or in 
combination, could be a risk factor for carbamazepine-induced mild hepatotoxicity (96). 
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GSTM1(-) and GSTT1(-) were chosen due to their association with troglitazone-induced 
liver toxicity, a drug of the thiazolidinedione class used as an anti-glycemic agent whose 
licence was withdrawn following idiosyncratic hepatotoxicity. The study followed 192 
Japanese epilepsy patients treated with carbamazepine, and the genotypes of GSTM1(-), 
GSTT1(-), and of microsomal epoxide hydrolase-3 and 4 (mEH-3, mEH-4), were 
determined. mEH is an enzyme involved in a wide range of reactions involving epoxide 
intermediates, where it is responsible for the addition of water to these substrates. The 
proportion GSTM1 null and GSTT1 null genotypes in their cohort were reported as 55.7% 
and 39.6%, respectively. In patients with these genotypes, the alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) were abnormally elevated in 24% of the 
GSTM1 null patients, and 32.3% of the GSTT1 null patients, with levels rose by 
approximately 2.3- and 1.8-times that of the normal limit. When comparing both ALT 
and AST levels in the GSTM1 null vs. GSTM1 present genotypes, the levels were 
significantly higher in the former  (ALT - p = 0.007 and AST – p = 0.004). The levels of 
ALT was significantly higher in GSTM1-/GSTT1- than in GSTM1+/GSTT1- and 
GSTM1+/GSTT1+ (p = 0.01 and p = 0.01, respectively). Serum levels of AST was 
significantly higher in both GSTM1-/GSTT1- and GSTM1-/GSTT1+ than they were in 
GSTM1+/GSTT1+ (p = 0.02 and p = 0.003, respectively). Genotype of mEH showed no 
significant association with hepatotoxicity. In summary, the group suggested that the 
GSTM1 null genotype may be significantly associated with carbamazepine 
hepatotoxicity. 
Interestingly, a similar study was undertaken by Fukushima et al (97) who looked into the 
effects of the mu null genotype either alone, or in combination with, the theta null 
genotype on mild hepatotoxicity in patients treated with VPA. Hepatotoxicity was 
defined as a rise above normal levels of ALT, AST, γ-glutamyltranspeptidase (GGT) and 
total bilirubin in 149 Japanese patients with a diagnosis of epilepsy. The odds ratio (OR) 
of the GSTM1- vs. GSTT1+ genotype and the GSTM1-/GSTT1- vs. GSTM1+/GSTT1+ 
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genotypes for the increase of GGT over the normal limit were 2.3 (95% CI 1.1 – 7.2) and 
6.5 (95% CI 1.5 – 28), respectively. Liver function tests were not significantly affected by 
the GSTT1 genotype alone. In patients treated with VPA for greater than 6 months, ALT, 
AST and GGT were all significantly raised in the GSTM1- genotype compared to the 
GSTM1+ genotype. The authors therefore concluded that both GSTM1- and GSTM1-
/GSTT1- genotypes may be genetic risk factors for the particular increase of GGT in 
epilepsy patients treated with VPA.  
In a research project conducted by Shang et al (81), 32 clinical cortex specimens were 
obtained following neurosurgical removal for intractable epilepsy. Several structural 
pathologies were seen, including hippocampal sclerosis, arteriovenous malformation, old 
infarct, and viral encephalitis. Eight non-epileptic patients who had undergone 
neurosurgery for arteriovenous malformations for reasons other than epilepsy were used 
as controls.  Patients had been treated for over two years with at least 3 antiepileptic 
drugs, including phenytoin, phenobarbital, carbamazepine, valproate and topirimate to no 
effect, with patients experiencing at least 3 seizures per month in the preceding 6 months.  
Immunohistochemical techniques were employed to detect three GST isoforms in the 
cortex specimens: alpha, mu and pi. GSTA was not found in any specimens; GSTM was 
found in 63% of controls and 53% of intractable epileptic specimens; and GSTP showed 
immunoreactivity in 66% of the epilepsy patients compared with 50% of the controls (p < 
0.01). These results suggest that high levels of GST pi may contribute to refractory 
epilepsy. 
Whilst the pathophysiology of epilepsy is poorly understood, it is clear that there exists 
abnormal neuronal cellular function within the central nervous system. Further, in the 
pharmacoresistant phenotype, there may be local metabolic reasons as to why 
antiepileptic medications fail to provide adequate control of seizures. With the role of 
GSH and GST well-described in the homeostasis of cellular redox balance and in the 
elimination of xenobiotics, it is plausible that polymorphic variation within GST may 
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contribute to neuronal dysfunction that manifests as epilepsy, or indeed local increased 
metabolic activity may interfere with antiepileptic drug metabolism. A recent meta-
analysis of two genome-wide association studies highlighted SNP variants in GSTA4 to 
be associated with pharmacoresistant epilepsy.  
 
3.3. Pharmacogenetics and single nucleotide polymorphisms 
Pharmacogenetics comprises the study of how the pharmacokinetic and 
pharmacodynamic factors of a drug vary between individuals owing to genetic 
differences in the population. It is thought that polymorphisms in drug transporters, 
channels, metabolising enzymes, etc, may explain to some degree the dose-response 
variation seen in clinical medicine, and may indeed explain the pharmacoresistant 
phenotype observed in several diseases (98). The ultimate goal of this area of science is 
personalised medicine – genotyping of individuals in order to predict their response to a 
drug, or predict which members of the population may react adversely to a particular 
drug.  
Since the advent of pharmacogenetics, many drugs, their target sites, and metabolising 
enzymes, have been extensively researched. A particular example is outlined with 
warfarin, a vitamin-K antagonist used widely as an anticoagulant for various indications. 
In dosing a patient with warfarin, only the weight of the patient is taken into 
consideration, with no other predictors of how well the patient will respond taken into 
account. Maintaining serum concentrations within the therapeutic index requires constant 
monitoring and dose adjustment owing to inter-individual drug response, and it is thought 
this variation may be secondary to genetic differences, particularly polymorphisms in the 
genes VKORC1 and CYP2C9 (99-101). In the United States, genetic testing is now 
indicated in order to better predict response to warfarin, and it is hoped that this pre-
prescription testing many occur for more drugs in the future (100, 102).  
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Single nucleotide polymorphisms (SNPs) are variations within a single nucleotide, such 
that one base is switched for an alternate. In describing these variations, we refer to a 
SNP as having two alleles, such that a change from a cytosine (C) to thymine (T) (C>T) 
SNP would have C and T alleles, and the individual could be genotype CC, CT or TT. 
SNP variation is the commonest form of genetic variation, and there are thought to be in 
excess of 3 million common SNPs within the human population (12). The vast majority 
of these polymorphisms are in regions of the genome that have no functional significance, 
with protein function remaining unaltered. In order of perceived functional significance, 
there major categories of SNP are: 
1) Non-synonymous 
a. Nonsense 
b. Missense 
2) Splice site 
a. 5’ splice site – upstream of the gene 
b. 3’ splice site – downstream of the gene 
3) mRNA untranslated region (mRNA UTR) 
a. 5’ UTR – upstream of the gene 
b. 3’ UTR – downstream of the gene 
4) Synonymous 
5) Intronic  
SNPs within each of the above genomic regions may affect protein structure and, hence, 
may affect function in a variety of ways. Nonsense SNPs generally affect protein function 
most drastically, where they are responsible for premature stop-codons and the truncation 
of the polypeptide. It is also known that nonsense mutation can result in mRNA decay, 
resulting in the complete absence of the gene product – nonsense-mediated decay (103).  
Missense SNPs are responsible for the change in the amino acid that occur secondary to 
an alternate codon being produced. The resultant change may or may not result in a 
functional difference in the protein, as the substituted amino acid may or may not cause a 
significant change.  
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The process whereby intronic regions of DNA are removed and exonic regions are joined 
is termed splicing. SNPs within the splicing sites (either up- or downstream) of the gene 
thereby result in defected amino acid sequence and may impact upon the specificity of the 
transcribed protein.  
SNPs within the mRNA UTR regions can also occur either up- or downstream of the 
gene. These regions of DNA are implicated in the binding of transcription factors and in 
the stability of the mRNA, and thereby variation within these sites may affect protein 
synthesis and overall protein structure in these ways. 
Synonymous SNPs result in codon-triplets that code for the same amino acid as 
previously, and it was therefore first thought that these genetic variants were of no 
functional consequence. However, it is now recognised that certain codons translate for 
amino acids more readily and efficiently than others, and therefore these SNPs may also 
have a consequence for the overall gene product if the polymorphism is at a critical 
region.  
Those SNPs that exist in the non-coding, intronic region of the gene are thought to carry 
the least functional significance. Whilst these variants are not directly associated with the 
overall three-dimensional structure of the protein, they may have a role in the stability of 
the gene and in gene expression during the transcription-translation process.  
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3.4. Aims 
The aim of this study was to further investigate the association of GSTA4 gene variants 
with treatment outcome in newly-diagnosed epilepsy. This was undertaken by detailed 
analysis of multiple polymorphic sites across the GSTA4 gene in an effort to validate the 
original observation, and to identify the potentially causal variant. The analysis was 
achieved by selecting 17 SNPs from across the GSTA4 gene that represented variation at 
a total of 48 loci, genotyping those SNPs using both TaqMan real-time PCR and 
Sequenom MALDI-TOF MS methods, and performing binary logistic regression and Cox 
multivariate regression analysis of SNP genotype against treatment response with 
adjustment for clinical covariates as described in the original GWAS analysis.  
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Chapter 4: Methods 
4.1. SNP selection 
4.1.1. HapMap  
The HapMap project is an international collaboration between six countries whose aim is 
to produce a publically accessible database of the known genetic variation within Homo 
sapiens in order to advance the research of medical genetics and their effects on disease.  
The HapMap database (accessible via: http://hapmap.ncbi.nlm.nih.gov/) was used to 
obtain the chromosomal coordinates of the GSTA4 gene using the genome browser #27 
feature (details given below). Ten kilobases (kb) of DNA sequence were added up- and 
down-stream of these coordinates such that the 5’ upstream and 3’ downstream regions of 
the gene were confidently included in the search.  
Table 4.1. Chromosomal coordinates of the GSTA4 gene 
Gene Chromosomal position (kb) Expanded position 
(±10kb) 
GSTA4 Chr 6: 52,950 – 52,968 Chr 6: 52,940 – 52,978 
 
4.1.2. HaploView 
HaploView (version 4.2) is a bioinformatics software package that allows linkage 
disequilibrium (LD) and haplotype block analysis, haplotype population frequency 
estimation, and SNP and haplotype association testing amongst its features. The 
coordinates obtained from the HapMap database were entered into HaploView and a 
comprehensive list of SNPs representing variation across the GSTA4 gene region (± 
10kb) in the Caucasian only population was generated.  
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This list was refined within HaploView by applying the following restrictions and 
rescoring the genetic markers: 
- Hardy-Weinberg (HW) p-value = 0.001 
- Minimum genotype: 75% 
- Maximum number Mendelian errors: 1 
- Minimum minor allele frequency: 0.001 
This resulted in the identification of 48 SNPs representative of variation across the 
GSTA4 gene region. Thereafter, the ‘Tagger’ function within HaploView was employed 
to generate a list of tagging SNPs that, owing to the LD structure across the GSTA4 gene 
region, would serve as markers for these 48 alleles and thereby reduce the number of 
SNPs required to genotype. The following criteria were set for the identification of 
tagging SNPs in Tagger: 
- Pairwise tagging only 
- r2 value = 0.8 
- LOD threshold for multi-marker tests = 3.0 
The resulting list of tagging SNPs was manipulated to include SNPs of specific interest 
(force-inclusion). These are listed in table 3.2 below. Force inclusions included SNPs 
typed in the original GWAS, those for which evidence of association existed, and those in 
putatively functional locations within the gene (i.e., coding regions, splice sites, promoter 
region). The latter characteristics were determined by reference to the National Centre for 
Biotechnology Information (NCBI) website (accessible via: 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp). 
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Table 4.2. List of forced inclusion SNPs 
 
 
 
 
 
 
This resulted in the final identification of 17 SNPs across the GSTA4 gene region that 
would effectively (r
2
=0.978) capture all known genetic variation. Those tagging SNPs are 
listed in table 3.3, together with the alleles captured by each SNP. 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Reason 
rs384505 Reported as significant in AUS 
cohort 
rs622902 Typed in GWAS 
rs4147617 Potential missense SNP, though 
with very low MAF 
rs316132 Typed in GWAS 
rs1802061 Synonymous SNP 
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Table 4.3. Tagging/test SNPs with captured alleles 
Test Captured alleles 
rs384505 rs384505 
rs622902 rs622902 
rs4147617  rs4147617 
rs316132 rs612483, rs426013, rs584124, 
rs316133, rs670960, rs316141, 
rs316129, rs316132, rs316140, 
rs613764, rs316131 
rs1802061  rs17615213, rs1802061, 
rs4986947, rs17614751 
rs316128 
 
rs375872, rs316135, rs375887, 
rs428957, rs449690, rs385636, 
rs316128, rs419129, rs426169, 
rs387853 
rs13191212  rs672822, rs669674, rs654144, 
rs11967816, rs13191212, 
rs508078 
rs6922246  rs6922246, rs1032419, 
rs9463851 
rs34511626  rs13219629, rs34511626 
rs6904769  rs6904769, rs7496 
rs3734431  rs3734431 
rs16883343  rs16883343 
rs17608022  rs17608022 
rs6904771 rs6904771 
rs396216  rs396216 
rs3756980  rs3756980 
rs2397136  rs2397136 
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4.2. Preparing a working-stock of DNA 
Prior to plating out the DNA, each of the SANAD and Glasgow samples was 
Nanodroped® in order to obtain their original concentration. Thereafter, nanopure water 
was added to the stock DNA samples accordingly in order to obtain working-stock 
aliquots of 20µL at a concentration of 20ng/µL.  
For stock concentrations that were too low, or for those samples that contained 
insufficient volume, these patients were excluded from the original eligible list. This 
resulted in 35 stock samples that were unusable from the SANAD cohort. All samples 
from the Glasgow cohort were usable. 
The working-stock DNA was plated out into 96-well plates. For purposes of quality 
control, wells B3 and D7 were filled with nanopure water (blanks), and 8 controls taken 
from random wells were dispensed into wells H8 – H12 such that following the 
genotyping the results could be checked for concordance. The plates were then stored at -
20
o
C until required.  
 
4.3. TaqMan® genotyping 
PCR is a molecular technique used to amplify a specific segment of DNA across several 
orders of magnitude such that there are sufficient copies to be analysed. The technology is 
now extremely commonplace, and its uses include amplification of nucleic acids in 
medical diagnostics, genotyping and forensic science. TaqMan® PCR is one of several 
types of ‘real-time’ PCR methods, so called owing to the ability to quantify, in real-time, 
the absolute increase in amplified DNA as the reaction proceeds. The key difference in 
this method is the employment of a TaqMan® probe. The probe is an oligonucleotide and 
contains a reporter flurophore covalently attached to the 5’-end of the molecule. At the 
3’-end is a covalently-bonded quencher molecule. Whilst the two molecules are attached 
to the probe – prior to the action of Taq polymerase – the quencher prevents fluorescence 
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from the reporter molecule via fluorescence resonance energy transfer and therefore 
inhibits detection by the PCR detector. The probes are designed such that they anneal to a 
region of DNA that is amplified by a specific set of primers. When the Taq polymerase 
adds nucleotides to the template DNA, the reporter molecule is separated and is free to 
emit fluorescence that can be detected. Therefore, the amount of fluorescence emitted 
increases exponentially commensurate with the quantity of DNA and can be reported in 
real-time.  
4.3.1. Plating DNA for PCR genotyping 
The stored working-stock DNA was allowed to thaw from -20
o
C at room temperature and 
centrifuged at 1,500rpm for 30 seconds. Using an 8-channel multi-pipette, 1µL (20ng) of 
working-stock DNA was transferred into the alternate wells of a 384-well plate. In this 
way, four 96-well plates were transferred into one 384-well plate, and then placed in a 
vacuum centrifuge at room temperature for 5 minutes until the aqueous supernatant had 
evaporated and the dried DNA was left. If required, this could be sealed and stored at -
20
o
C for future use. 
4.3.2. Preparation of polymerase chain reaction solution  
For each full, and each half, 384-well plate (depending on how many samples were being 
genotyped), the quantities shown in table 3.4 were prepared in either a 5mL bijou tube, or 
a 1mL eppendoft tube, again depending on the quantity required. 
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Table 4.4. Reagents and volumes for PCR mix 
Reagent Storage 
(temperature) 
384 plate Vol. 
(µL) 
192 plate Vol. 
(µL) 
Storage 
Temp (
O
C) 
Nanopure 
water 
Sterile bijou tube 
(room) 
950 475 Room 
TaqMan 
master mix 
PCR fridge (5
o
C) 1,000 500 -20 
SNP PCR freezer (-20
o
C) 50 25 -20 
Total  2,000 1,000  
 
The SNP was removed from the freezer and allowed to thaw in the PCR room at room 
temperature. Once thawed, the reagents detailed above were pipetted into a bijou tube 
under a PCR-only fume cupboard and then mixed using a whirlmixer® for 10seconds. 
Into a 96-well ‘v-plate’, 250µL of the PCR mix was pipetted into each well in the first 
column, A1 – H1. An 8-tip multi-channel pipette was then employed in order to pipette 
5µL of the PCR mixture into each of the 384 wells containing the dehydrated DNA. The 
plate was sealed with a clear adhesive PCR LASER cover thereafter, mixed using a 
whirlmixer® for 30seconds, and centrifuged at 3,000rpm for one minute.  
4.3.3. PCR reaction 
The sealed plate was placed in the automated draw of the TaqMan PCR machine and the 
software set-up and run as per the manufacturer’s instructions. 
 
4.4. Sequenom MALDI-TOF genotyping 
Fourteen of the seventeen SNPs were genotyped using the Sequenom platform, a matrix 
assisted laser desorption/ionisation time of flight mass spectrometry technology (MALDI-
TOF MS). Using the MySequenom® online gene tool facility (accessible via: 
https://www.mysequenom.com/Home; login details required) the experimental design 
was constructed by Sequenom in the manner detailed below. 
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4.4.1. MySequenom  
The ‘MySequenom’ facility enables easy online assay design using a 5 step tool. The 
steps involved include: 
1. Retrieve and format sequences 
- This step involves the uploading of the SNP (by rs identification) from the 
NCBI database as described previously. 
2. Find proximal SNPs (ProxSNPs) 
- SNP sequences are then aligned to the specified genome followed by re-
formatting with registered SNPs in close proximity to the desired assay. 
3. Identification of optimal primer areas 
- Next, reformatting of the SNP sequences in order to demark PCR 
amplification primers is carried out, which will result in a unique 
amplification product.  
4. Assay design 
- The final assay design is produced at this stage. 
5. Validation (pleXTEND) 
- The final step in the process is the validation step, whereby the software 
analyses the final assay design in order to identify any unintended cross-
amplification products that may lead to false positive signalling in the mass 
spectrometer.   
-  
4.4.2. Plating DNA for Sequenom Genotyping 
DNA from the working-stock, stored at -20
o
C, was allowed to thaw at room temperature. 
Two microliters (40ng) was pipetted using an 8-tip multi-channel pipette into a 96-well 
PCR plate and dried down using a vacuum centrifuge at room temperature for 10 minutes.  
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4.4.3. Preparation of plex primer mix 
For each of the 14 SNPs, the following primers were added into a 1,000 µL eppendorf 
tube to produce a solution containing 500µL at 0.5µM. This was then placed in the 5
o
C 
PCR fridge until required: 
- 5µL of forward primer (x14) 
- 5µL of reverse primer (x14) 
-  360µL nanopure water  
Next, the PCR reaction mixture was made under a fume cupboard in the PCR room 
according to table 2.4.  
Table 4.5  Sequenom PCR preparation mix  
Reagent Volume for Single 
Reaction 
Volume for 24-plex 
(384-wells) 
Storage Temp 
(
o
C) 
Nanopure water 2.85 µL 1368.00 µL Room 
PCR buffer (10x) 0.625 µL 300.00 µL -20 
MgCl2 (25mM) 0.325 µL 156.00 µL -20 
dNTP mix (25mM) 0.10 µL 48.00 µL -20 
Primer mix 
(0.5µM) 
1.00 µL 480.00 µL -20 
Hot Star Taq 
(5U/µL) 
0.10 µL 48.00 µL -20 
Total Volume 5.00 µL 2400.00 µL  
 
 
The reagents were stored according to the temperatures detailed above, and allowed to 
thaw at room temperature. They were then mixed in a sterile 5,000µL bijou tube. 
Thereafter, the solution was mixed using a whirlmixer® for 30 seconds, and then stored 
on ice to prevent action of the Taq enzyme.   
Using a 96-well ‘v-plate’, 300µL of the PCR mix was pipetted into wells A1 – H1. An 8-
tip multi-channel pipette was then used to transfer 5µL of this reaction mix into each of 
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the 384 wells of the dehydrated DNA. The plate was sealed with an adhesive PCR plate 
seal, whirlmixed® for 1 minute, and centrifuged for 1 minute at 2,000rpm. 
4.4.4. PCR Reaction 
The initial PCR reaction was run using a PCR cycler as per the manufacturer’s 
instructions.  
4.4.5. Shrimp alkaline phosphatase 
It is necessary, prior to the addition of further reaction agents in subsequent stages, to add 
shrimp alkaline phosphatase (SAP) enzyme to the previous PCR products in order to 
prevent the interference of unincorporated deoxyribonucleotide triphosphate (dNTP). The 
SAP enzyme results in the dephosphorylation of the excess dNTP and renders it inactive 
for further reactions.  
4.4.5.1. Preparation of the SAP reagents 
The SAP enzyme solution was prepared according to the volumes given below. 
Table 4.6. SAP Enzyme Reagent Preparation 
Reagent Volume for Single 
Reaction 
Volume for 384-
wells 
Storage Temp 
(
o
C) 
Nanopure water 1.53 µL 810.78 µL Room 
hME Buffer (x10) 0.17 µL 90.08 µL -20 
Shrimp Alkaline 
Phosphatase 
0.30 µL 158.98 µL -20 
Total Volume 2.00 µL 1059.84 µL  
  
The SAP reagents were taken from the freezer and allowed to thaw at room temperature. 
Once thawed, the reagents were added into a sterile 5,000µL bijou tube according to the 
quantities detailed above. The solution was mixed by a whirlmixer® for 30 seconds, and 
stored on ice to prevent any action or denaturation of the enzyme during further plate 
preparation.  
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Eighty-five microliters of the SAP enzyme mixture was then pipetted into wells H1 – 
H12 of a 96-well ‘v-plate’. An 8-tip multi-channel pipette was then used to dispense 
10µL from row H into each well in rows A – G. 
4.4.5.2. Addition of SAP enzyme to DNA-containing plate 
Prior to the addition of the SAP enzyme, both the 96-well SAP-containing plate, and the 
384-well PCR plate, were sealed and centrifuged for 1 minute at 2,000rpm.  
Using the automated Matrix Liquid Handler (MLH), 2µL of SAP enzyme mixture was 
added to each of the 384 DNA-containing wells containing the previous PCR reaction 
products. The software protocol, produced by Sequenom for the use of this machine, was 
consulted in order to operate the MHL.  
4.4.5.3. SAP enzyme reaction 
The SAP reaction was undertaken on a PCR cycler as per the manufacturer’s instructions.  
4.4.6. iPLEX® gold reaction mixture  
Details of the mass of each extension primer were supplied by the manufacturers in a 
table that could be utilised for the preparation of the extension primer mix. A total of 14 
extension primers were used (14 SNPs being analysed) and they were consequently 
arranged in ascending order according to their mass. Thereafter, the primers were 
required to be split into 4 groups, again according to their mass, which yielded two 
groups of four, and two groups of 3, as detailed in the 4-step adjustment process in the 
table below.  
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4.4.6.1. iPLEX® gold extend primer mix reaction 
Table 4.7  4-Step adjustment table for extension primer mix 
Extend 
Primer 
Group 
Final 
Con
c
/primer 
Volume/primer N
o
 
Primers/group 
Total Vol 
Volume 
1 7µM 8.75µL 4 35µL 
2 9.3µM 11.63µL 4 46.52µL 
3 11.6µM 14.58µL 3 131.22µL 
4 14µM 17.5µL 3 157.5µL 
Nanopure 
Water 
   379.76µL 
Total Volume    750µL 
 
The extension primers were stored in the PCR fridge at 5
o
C until required. The reagents 
were mixed into a sterile 1,000µL eppendorf tube, and mixed using a whirlmixer® for 30 
seconds. The solution was then stored back in the PCR fridge at 5
o
C until it was required. 
4.4.6.2. iPLEX® gold reaction mixture 
Following the preparation of the extension primers, the iPLEX® reaction mixture was 
made according to the reagents and volumes outlined below. 
Table 4.8  iPLEX reaction reagents and volumes 
Reagent Volume for Single 
Reaction 
One-plex Volume Storage Temp 
(
O
C) 
Nanopure water 0.755µL 400.01µL Room 
iPLEX® buffer 0.2µL 105.98µL -20 
iPLEX® termination 
mix 
0.2µL 105.98µL -20 
Extension primer mix 0.804µL 426.06µL -5 
iPLEX® enzyme 0.04µL 21.20µL -20 
Total 2.0µL 1059.34µL  
 
All frozen products were allowed to thaw at room temperature, and were mixed in a 
sterile 5,000µL bijou tube and mixed with a whirlmixer® for 30 seconds. The extension 
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primer mix that was produced in the previous step (3.5.1) was taken from the -5
o
C fridge 
and allowed to reach room temperature. 
Into a new 96-well ‘v-plate’, 85µL of the iPLEX® reaction cocktail were pipetted into 
wells H1 – H12. Following this, an 8-tip multi-channel pipette was used to draw 10µL 
from row H and dispensed into each of the wells in rows A – G.  
4.4.6.3. Addition of iPLEX® gold reaction mixture to DNA-containing plate 
Using the automated matrix liquid handler (MLH), 2µL of the iPLEX® gold reaction 
cocktail was added to the 384-well DNA-containing plate as per the manufacturer’s 
instructions.  
The plate was then sealed and centrifuged for 1 minute at 2,000rpm ready for the final 
PCR reaction. 
4.4.6.4. iPLEX® reaction 
The final iPLEX® reaction was carried out on the standard PCR cycler as per the 
manufacturer’s instructions.  
4.4.6.5. iPLEX® reaction products – clean-up 
The purpose of this stage is to maximise the data quality obtained via the mass 
spectrometry by removing excess ions and unincorporated reaction products from the 
IPLEX® reaction. This is done via the addition of spectroCLEAN resin and desalts the 
mixture via cation exchange.  
SpectroCLEAN resin was applied to the left-hand side of a 6mg dispenser containing 384 
wells. A Perspex plate is then used to spread the resin evenly across all 384 wells, with 
any excess recycled for future use. Once distributed across the dimple plate, the 384-well 
DNA-containing plate is inverted over the resin plate and again turned such that the resin 
drops into the PCR plate. This was then sealed and placed between two secure 
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polystyrene blocks in the Heidolph-Reax 2 rotator and allowed to rotate for 10 minutes at 
speed level 1 (slowest speed setting). 
Once the resin-DNA mixture had been thoroughly mixed, the plate was centrifuged for 5 
minutes at 3,000rpm in order to ensure the aqueous DNA mixture was the supernatant.  
 
4.4.6.6. Dispensing of the iPLEX® reaction products into the SpectroCHIP® 
Dispensing of the PCR reaction products onto the spectroCHIP® for MALDI-TOF 
analysis was by the automated MassARRAY® nanodispenser. This machine accurately 
pipettes between 15-25µL of the sample onto the matrix of the spectroCHIP®, whereby 
co-crystallisation occurs for the MALDI-TOF mass spectrometry stage.  
The MassARRAY® nanodispenser was first prepared and conditioned as per the 
manufacturers protocol, and includes washing and sterilisation of the pin heads using an 
ultrasonic ethanol sonicator bath and pin drying. Calibrate solution was then taken from 
the PCR freezer (-20
o
C)
 
and allowed to thaw at room temperature, and 70µL pipetted into 
the calibrant reservoir. A spare spectroCHIP® was then used in order to ascertain the 
accuracy of the nanodispenser, and once this was satisfactory, a new spectroCHIP® was 
placed in the chip holder and the programme run to spot the chip.  
 
4.4.7. Matrix assisted laser desorption/ionisation time-of-flight mass 
spectrometry (MALDI-TOF MS) 
MALDI-TOF MS is a technique used in mass spectrometry that enables the detection and 
analysis of biomolecules such as proteins, sugars, DNA and oligonucleotides. The 
process by which the technology works is two step: first, desorption of the sample into 
the chip matrix is triggered by an ultraviolet laser of typical wavelength 337nm. The 
second step is ionisation of the ablated species, which enables acceleration by means of 
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an electric field. All molecules are given the same kinetic energy, and thus determination 
of the anylate is dependent on mass by means of its ‘time of flight’.   
Figure 4.1 A schematic of a MALDI-TOF MS system.                                                    
Taken from. http://www.giga.ulg.ac.be/jcms/cdu_15169/maldi-tof/tof-bruker-ultraflex-ii-
tof/tof-april-2005 
The anylate is desorbed into the matrix and ionisation by way of a UV laser occurs. The 
ionised species are deflected through an electric field with their time of flight dictated by 
their mass. 
4.4.7.1. Analysis of the SpectroCHIP®  
Upon completion of sample dispensing, the chip was transferred to the MassARRAY® 
instrument using magnetic tongs in order to prevent contamination. The chip was placed 
into the mass spectrometer and the vacuum established. Once complete, the laser 
desorption/ionisation process was initiated as per the manufacturers protocol, and the 
genotypes called in real-time according to their time of flight.  
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4.4. Data and quality control 
Blanks and repeats were incorporated into each plex as detailed previously.  Blank wells 
containing nanopure water would be reported as having no genetic material, and the 
repeats were cross-referenced with the identical samples to ensure concordant results. 
Where this was not the case, they were repeated or excluded from the results. 
Prior to statistical analyses, both clinical and genotyped data were subject to the 
following inclusion criteria: 
4.4.1. SNP control 
Only those SNPs successfully genotyped in ≥ 90% of patients were to be included. No 
SNPs were excluded on the basis of this criterion.   
4.4.2. DNA genotype  control 
Only those patients in whom ≥ 90% of SNPs were genotyped were included. This 
resulted in the exclusion of 36 samples from the SANAD cohort and 28 samples from the 
Glasgow cohort.  
4.4.3. Hardy-Weinberg equilibrium 
In order to ensure the allele frequencies of the cohorts were representative of the general 
population, Hardy-Weinberg calculations were carried out on our data at the p=0.001 
significance level.  On this basis, one SNP (rs4147617) was excluded, resulting in 16 
SNPs for analysis. 
4.4.4. Matching clinical and genotype data 
Both clinical and genotype data for each patient was required in order to complete the 
statistical analysis. When data were not present for both, the patients were removed from 
the analysis.  
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These criteria resulted in the following patients from each cohort eligible for statistical 
analysis: 552 SANAD patients and 442 Glasgow patients.   
 
4.5. Statistical Methods 
4.5.1. Clinical covariates and data coding 
The clinical covariates included in the analysis reflect those found to be significantly 
associated with outcomes in the earlier SANAD GWAS analysis. Data for neurological 
deficit and neuroimaging was not available in the Glasgow database and were therefore 
excluded. The included covariates were: 
- Age 
- Sex 
- Epilepsy type (partial, generalised, unclassifiable) 
- Number of pre-treatment seizures (2, 3, 4, 5, >5) 
- AED treatment (sodium valproate or gabapentin vs. neither) 
- EEG findings (normal, non-specific, epileptiform, not-done) 
Following collection of the experimental and clinical data, the genotypes and clinical 
covariates were coded as detailed in table. 
 
 
 
 
 
 
75 
 
Table 4.9  Data coding for statistical analysis 
Variable Coding reference 
Age Age in years at first AED treatment 
Sex 0 – male; 1 – female 
Epilepsy type LRE – 1; IGE – 2; UNC – 3 
N
o
 pre-treatment seizures 2 – 1; 3 – 2; 4 – 3; 5 – 4; >5 - 5 
AED treatment VPA/GBP – 0; neither – 1 
EEG report Normal – 1; non-specific – 2; epileptiform 
– 3; not-done - 4 
Genotype Homozygous wild – 0; heterozygous – 1; 
homozygous mutant – 2 
Time to 12-month remission Earliest of days to 12-month remission and 
days to end of follow-up (censoring) 
Remission during follow-up? No – 0 (censored observations); yes – 1 
(events) 
 
LRE: localisation-related epilepsy; IGE: idiopathic generalised epilepsy; UNC – 
unclassifiable epilepsy; AED: antiepileptic drug; VPA: sodium valproate; GBP: 
gabapentin; EEG: electroencephalogram 
 
4.5.2. Statistical analysis 
Two outcomes were investigated:  
1) Remission of epilepsy: ‘yes’ or ‘no’  
2) Time to 12-month remission  
Analyses of association between each SNP and the first outcome were undertaken using a 
binary logistic regression model. For each SNP in turn, two models were fitted: the 
‘baseline model’, which included all of the six clinical characteristics recorded at baseline 
as covariates (outlined previously), and the ‘genotype model’, which was the same as the 
baseline model but also included a covariate to represent the SNP of interest. The two 
models were compared using the likelihood ratio test, with a significant result suggesting 
a statistically significant association between the SNP and outcome. 
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Analyses of association between each SNP and time to 12-month remission statistics 
were carried out using Cox proportional hazards multiple regression. Again, for each SNP 
in turn a baseline model including the six clinical covariates adjusted for above, and a 
genotype model which also included the SNP of interest, were fitted and compared using 
the likelihood ratio test. Kaplan-Meir (KM) plots were prepared for significant 
associations to illustrate the log survival function between the genotype groups. KM plots 
are a graphical representation of the survival function or time to event which, in this 
instance, is the time to 12-month remission of seizures. At any point, the graph illustrates 
the proportion of patients free from disease (seizures) and, therefore, a plot that tends to 0 
quickly over time indicates a worse prognosis.  
For stage one of the analysis, the tests of association were conducted in the SANAD 
cohort whilst for stage two the analyses were replicated in the Glasgow cohort. Finally, 
for stage three, a pooled analysis including both cohorts was undertaken. In the latter, an 
additional covariate representing study cohort (SANAD = 0; Glasgow = 1) was 
introduced to the baseline and genotype models. For each stage, the false discovery rate 
(FDR) was calculated for each association to account for the multiplicity of tests 
undertaken. A FDR<0.05 was assumed to represent statistical significance. The FDR 
were calculated using the ‘p.adjust’ function in the statistical package, ‘R’.  
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Chapter 5: Results 
The statistical package SPSS (version 20) was used to conduct the statistical analyses of 
association.   
5.1. Linkage disequilibrium  
Linkage disequilibrium (LD) is the non-random relationship observed between alleles at 
different chromosomal loci. Below are LD plots for each of the SANAD and Glasgow 
patient cohorts, including a plot for the combination of both datasets.  
HaploView version 4.2 was used in order to create an LD plot of the SNPs used in this 
analysis. The numbers in each square represent the percentage probability that those 
SNPs are inherited together – that is, how much they are in linkage disequilibrium with 
one another. 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. SANAD cohort LD plot 
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Figure 5.2. Glasgow cohort LD plot 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. SANAD and Glasgow combined LD plot 
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5.2. Descriptive statistics  
5.2.1. SANAD Cohort 
Five-hundred and forty-one patients constituted the SANAD dataset. Of these, 287 
(53.0%) were male and 254 (47.0%) were female. The range of ages amongst the patients 
was 18 – 99 years with a mean age of 64 years and a standard deviation of 17.8 years. For 
the majority of patients, their diagnosis was partial/localisation-related epilepsy with a 
total of 364 (67.3%) patients. Idiopathic generalised epilepsy was diagnosed in 84 
(15.5%) patients, and the remaining 93 (17.2%) patients’ epilepsy was unclassifiable. The 
number of pre-treatment seizures ranged from 2 – 10,003, with a median of 12. Sodium 
valproate or gabapentin was prescribed as the AED of choice in 137 (25.3%) patients, 
with the remaining 404 (74.7%) patients being prescribed a different AED. EEG findings 
were reported as normal in 225 (41.6%) patients, non-specific in 136 (25.1%) patients, 
epileptiform in 135 (25%) patients, and was not carried out in 45 (8.3%) of patients. Of 
this cohort, a total of 323 (59.7%) patients went into remission of their epilepsy during 
the follow-up period. The median time to 12-month remission was 538 days.  
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Table 5.1 Descriptive data for the SANAD dataset 
Clinical Covariate   
Sex Male 
Female 
287 (53.0%) 
254 (47.0%) 
Age Minimum 
Maximum 
Mean 
S.D. 
18 years 
99 years 
64 years 
17.8 years 
Epilepsy type IGE 
LRE 
UNC 
84 (15.5%) 
364 (67.3%) 
93 (17.2%) 
N
o
 pre-treatment seizures Minimum 
Maximum 
Median 
1 
10,003 
12 
AED treatment VPS or GBP 
Neither 
137 (25.3%) 
404 (74.7%) 
EEG report Normal 
Non-specific 
Epileptiform 
Not-done 
225 (41.6%) 
136 (25.1%) 
135 (25.0%) 
45 (8.3%) 
Proportion achieving 
remission 
Yes 
No 
323 (59.7%) 
218 (40.3%) 
Median time to 12-month 
remission 
 538 days 
  n = 541 
 
S.D.: standard deviation; IGE: idiopathic generalised epilepsy; LRE: localisation-related 
epilepsy; UNC: unclassifiable epilepsy; AED: antiepileptic drug; VPS: sodium valproate; 
GBP: gabapentin; EEG: electroencephalogram 
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5.2.2. Glasgow Cohort 
Three-hundred and ninety patients constituted the Glasgow dataset. Of these, 225 (57.7%) 
were male and 165 (42.3%) were female. The age of patients ranged from 13 – 81 years, 
with a mean of 37 years and a standard deviation of 17.3 years. Sixty-nine (17.7%) 
patients were diagnosed with idiopathic generalised epilepsy, 295 (75.6%) with 
localisation-related/partial epilepsy and the remaining 26 (6.7%) patients’ epilepsy was 
unclassifiable. Sodium valproate or gabapentin was the prescribed AED in 93 (23.8%) 
patients, with the remaining 297 (76.2%) patients being prescribed an alternative agent. 
EEG testing was reported as normal in 143 (36.7%) patients, non-specific in 106 (27.2%) 
patients, epileptiform in 94 (24.1%) patients, and was not conducted in 47 (12.1%) 
patients. The number of pre-treatment seizures in the Glasgow cohort were already 
censored and therefore the raw data for this covariate was not available. A total of 278 
(71.3%) patients achieved seizure remission, with a median time to 12-month remission 
of 550 days. 
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Table 5.2. Descriptive data for the Glasgow dataset  
Clinical Covariate   
Sex Male 
Female 
225 (57.7%) 
165 (42.3%) 
Age Minimum 
Maximum 
Mean 
S.D. 
13 years 
81 years 
37 years 
17.3 years 
Epilepsy type IGE 
LRE 
UNC 
69 (17.7%) 
295 (75.6%) 
26 (6.7%) 
AED treatment VPS or GBP 
Neither 
93 (23.8%) 
297 (76.2%) 
EEG report Normal 
Non-specific 
Epileptiform 
Not-done 
143 (36.7%) 
106 (27.2%) 
94 (24.1%) 
47 (12.1%) 
Proportion achieving 
remission 
Yes 
No 
278 (71.3%) 
112 (28.7%) 
Median time to 12-month 
remission 
 550 days 
  n=390 
 
S.D.: standard deviation; IGE: idiopathic generalised epilepsy; LRE: localisation-related 
epilepsy; UNC: unclassifiable epilepsy; AED: antiepileptic drug; VPS: sodium valproate; 
GBP: gabapentin; EEG: electroencephalogram 
 
 
 
 
 
 
 
84 
 
5.3. Binary logistic regression analysis 
 
Table 5.3. SANAD cohort 
SNP  -2 log 
likelihood 
baseline 
model 
-2 log 
likelihood 
genotype 
model 
p-value 
(likelihood 
test) 
FDR OR 95% CI 
rs7496 662.60 656.09 0.0107 0.0679 0.583 0.384 - 0.885 
rs316128 660.16 653.83 0.0119 0.0543 0.720 0.557 – 0.932 
rs316132 655.62 652.22 0.0652 0.199 0.783 0.604 – 1.015 
rs396216 659.67 659.61 0.806 0.878 1.034 0.788 – 1.357 
rs622902 661.31 658.63 0.102 0.271 0.808 0.625 – 1.044 
rs2397136 662.60 660.96 0.200 0.427 0.802 0.573 – 1.123 
rs3734431 660.75 660.48 0.0633 0.776 0.886 0.564 – 1.392 
rs3756980 656.89 656.69 0.655 0.776 1.075 0.785 – 1.474 
rs6904769 661.79 653.16 0.00331 0.0353 0.535 0.351 – 0.816 
rs6922246 657.47 645.94 0.000685 0.0109 0.562 0.401 – 0.786 
rs13191212 654.98 654.16 0.365 0.625 0.816 0.526 – 1.265 
rs13219629 657.02 656.22 0.371 0.625 1.196 0.806 – 1.776 
rs16883343 655.62 655.40 0.639 0.776 1.073 0.802 – 1.436 
rs384505 662.60 655.06 0.00603 0.0483 1.432 1.106 – 1.855 
rs1802061 662.60 662.55 0.823 0.878 0.940 0.547 – 1.617 
rs17608022 662.60 662.36 0.624 0.776 0.903 0.603 – 1.352 
 
FDR: false discovery rate; OR: odds ratio; CI: confidence interval  
Binary logistic regression analysis of the SANAD dataset found 3 SNPs (rs6904769, 
FDR = 0.0353, OR = 0.535, 95% CI 0.351 – 0.816; rs6922246, FDR = 0.0109, OR = 
0.0109, 95% CI 0.401 – 0.786; and rs384505, FDR = 0.0483, OR = 1.432, 95% CI 1.106 
– 1.855) to have a statistically significant association with remission of epilepsy. 
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Table 5.4. Glasgow cohort 
SNP  -2 log 
likelihood 
baseline 
model 
-2 log 
likelihood 
genotype 
model  
p-value 
(likelihood 
test) 
FDR OR 95% CI 
rs7496 438.86 438.61 0.617 0.859 1.140 0.678 – 1.918 
rs316128 439.68 438.99 0.406 0.685 1.150 0.828 – 1.598 
rs316132 430.42 428.95 0.225 0.609 1.225 0.881 – 1.704 
rs396216 435.84 434.51 0.249 0.612 1.230 0.863 – 1.753 
rs622902 437.63 435.16 0.116 0.609 1.299 0.935 – 1.806 
rs2397136 440.04 439.86 0.671 0.882 0.910 0.590 – 1.402 
rs3734431 437.25 436.30 0.330 0.684 1.360 0.723 – 2.555 
rs3756980 439.31 434.87 0.0351 0.562 1.553 1.018 – 2.371 
rs6904769 438.35 438.29 0.806 0.900 1.059 0.647 – 1.735 
rs6922246 439.31 439.23 0.777 0.900 0.939 0.618 – 1.426 
rs13191212 440.04 438.59 0.229 0.609 0.746 0.465 – 1.198 
rs13219629 440.04 436.50 0.0599 0.609 1.545 0.913 – 2.614 
rs16883343 427.15 427.13 0.888 0.916 0.972 0.663 – 1.424 
rs384505 440.04 439.98 0.806 0.900 0.958 0.686 – 1.338 
rs1802061 440.04 438.31 0.188 0.609 0.652 0.348 – 1.222 
rs17608022 440.04 439.45 0.442 0.684 1.205 0.774 – 1.951 
 
FDR: false discovery rate; OR: odds ratio; CI: confidence interval 
Following adjustment for FDR, no significant associations were observed with seizure 
remission in the Glasgow dataset.  
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Both the SANAD and Glasgow cohorts were combined in order to increase statistical 
power. The results of the analysis are shown below. 
Table 5.5. Combined cohorts 
SNP -2 log 
likelihood 
baseline 
model 
-2 log 
likelihood 
genotype 
model 
p-value 
(likelihood 
test) 
FDR OR 95% CI 
rs7496 1137.90 1135.32 0.108 0.266 0.775 0.568 – 1.057 
rs316128 1137.46 1135.15 0.129 0.279 0.860 0.707 – 1.045 
rs316132 1120.70 1120.20 0.479 0.667 0.931 0.764 – 1.135 
rs396216 1131.52 1130.67 0.357 0.543 1.103 0.895 – 1.360 
rs622902 1136.36 1136.30 0.806 0.833 0.976 0.803 – 1.187 
rs2397136 1139.92 1138.22 0.192 0.385 0.843 0.652 – 1.089 
rs3734431 1135.66 1135.60 0.806 0.833 1.045 0.737 – 1.483 
rs3756980 1132.18 1128.23 0.0469 0.150 1.277 1.001 – 1.628 
rs6904769 1137.24 1133.23 0.0452 0.150 0.731 0.539 – 0.992 
rs6922246 1134.73 1125.84 0.00287 0.0459 0.682 0.531 – 0.877 
rs13191212 1130.02 1126.33 0.0547 0.159 0.736 0.539 – 1.005 
rs13219629 1134.07 1129.70 0.0366 0.146 1.378 1.015 – 1.871 
rs16883343 1119.25 1119.04 0.647 0.796 1.054 0.841 – 1.320 
rs384505 1139.92 1135.22 0.0302 0.146 1.242 1.020 – 1.512 
rs1802061 1139.92 1138.32 0.206 0.388 0.770 0.514 – 1.152 
rs17608022 1139.92 1139.91 0.920 0.920 1.012 0.751 – 1.366 
 
FDR: false discovery rate; OR: odds ratio; CI: confidence interval 
By combining the SANAD and Glasgow cohorts, one association held significance 
(rs6922246, FDR = 0.0459, OR = 0.682; 95% CI 0.531 – 0.877). 
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5.4. Cox proportional hazards multiple regression analysis 
 
Table 5.6. SANAD cohort 
SNP -2 log 
likelihood 
baseline 
model 
-2 log 
likelihood 
genotype 
model 
p-value 
(likelihood 
test) 
FDR HR 95% CI 
rs7496 3677.07 3671.37 0.0169 0.0679 0.728 0.555 – 0.955 
rs316128 3676.41 3673.09 0.0684 0.199 0.865 0.741 – 1.011 
rs316132 3621.33 3619.13 0.138 0.315 0.887 0.757 – 1.040 
rs396216 3661.97 3661.84 0.718 0.821 1.030 0.877 – 1.210 
rs622902 3664.66 3662.40 0.133 0.315 0.888 0.760 – 1.037 
rs2397136 3677.07 3675.99 0.299 0.597 0.895 0.725 – 1.105 
rs3734431 3664.06 3663.63 0.512 0.776 0.914 0.696 – 1.201 
rs3756980 3648.62 3648.42 0.655 0.776 1.045 0.865 – 1.262 
rs6904769 3676.30 3669.19 0.00767 0.0491 0.698 0.529 – 0.921 
rs6922246 3662.08 3647.27 0.000119 0.00380 0.744 0.601 – 0.922 
rs13191212 3597.31 3596.76 0.458 0.733 0.900 0.679 – 1.192 
rs13219629 3660.04 3659.11 0.335 0.625 1.121 0.891 – 1.410 
rs16883343 3659.18 3658.96 0.639 0.776 1.042 0.877 – 1.238 
rs384505 3677.07 3672.22 0.0276 0.0983 1.192 1.019 – 1.393 
rs1802061 3677.07 3677.07 1 1 1.014 0.723 – 1.421 
rs17608022 3677.07 3677.06 0.920 0.950 1.015 0.796 – 1.295 
 
FDR: false discovery rate; HR: hazard ratio; CI confidence interval 
Using a Cox proportional hazards multiple regression model on the SANAD dataset, 2 
SNPs (rs6904769, FDR = 0.0491, HR = 0.698, 95% CI 0.529 – 0.921; rs6922246, FDR = 
0.00380, HR = 0.744, 95% CI 0.601 – 0.922) were found to show significant association 
with time to 12-month remission. The KM curves for these SNPs are shown below.  
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Figure 5.4.KM curve for rs6904769 (SANAD) 
  
 
 
 
 
 
 
 
 
 
Figure 5.5 KM curve for rs6922246 (SANAD) 
 
Figures 4.4 and figure 4.5 are Kaplan-Meir log survival functions for SNPs rs6904769 
and rs6922246 in the SANAD cohort, respectively. In both KM plots it can be seen that 
the patients with the mutant allele (2) are more likely to achieve seizure freedom than the 
heterozygous (1) and wild (0) types. 
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Table 5.7. Glasgow cohort  
SNP  -2 log 
likelihood 
baseline 
model 
-2 log 
likelihood 
genotype 
model 
p-value 
(likeliho
od test) 
FDR HR 95% CI 
rs7496 2934.83 2934.67 0.689 0.882 0.947 0.729 – 1.231 
rs316128 2946.27 2945.73 0.462 0.685 1.067 0.897 – 1.269 
rs316132 2858.79 2857.20 0.207 0.609 1.118 0.940 – 1.330 
rs396216 2933.23 2931.07 0.141 0.609 1.151 0.956 – 1.386 
rs622902 2933.92 2932.21 0.191 0.609 1.122 0.944 – 1.333 
rs2397136 2957.76 2957.72 0.841 0.898 0.978 0.776 – 1.232 
rs3734431 2943.77 2941.73 0.153 0.609 1.259 0.928 – 1.708 
rs3756980 2946.24 2940.76 0.0192 0.562 1.282 1.050 – 1.565 
rs6904769 2945.43 2944.63 0.371 0.685 0.892 0.692 – 1.151 
rs6922246 2946.24 2945.26 0.332 0.685 0.899 0.726 – 1.113 
rs13191212 2957.76 2957.19 0.450 0.685 0.897 0.674 – 1.193 
rs13219629 2946.24 2943.31 0.0869 0.609 1.240 0.975 – 1.578 
rs16883343 2878.84 2878.77 0.791 0.900 1.028 0.844 – 1.253 
rs384505 2957.76 2957.75 0.920 0.920 0.995 0.837 – 1.181 
rs1802061 2957.76 2957.19 0.450 0.685 0.873 0.609 – 1.252 
rs17608022 2957.76 2957.24 0.471 0.685 1.097 0.856 – 1.404 
 
FDR: false discovery rate; HR: hazard ratio; CI: confidence interval 
Cox proportional hazards multiple regression analysis on the Glasgow dataset failed to 
find significance in any of the 16 SNPs tested. 
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Table 5.8. Combined cohorts 
To further increase statistical power, the SANAD and Glasgow cohorts were once again 
combined. The results of this are shown below. 
SNP -2 log 
likelihood 
baseline 
model 
-2 log 
likelihood 
genotype 
model  
p-value 
(likelihood 
test) 
FDR HR 95% CI 
rs7496 7401.04 7396.61 0.0353 0.146 0.821 0.680 – 0.991 
rs316128 7413.28 7412.02 0.262 0.441 0.936 0.835 – 1.051 
rs316132 7256.36 7256.20 0.689 0.817 0.977 0.870 – 1.096 
rs396216 7382.69 7381.24 0.229 0.406 1.077 0.955 – 1.215 
rs622902 7386.65 7386.56 0.764 0.833 0.983 0.877 – 1.102 
rs2397136 7427.11 7426.19 0.337 0.540 0.927 0.794 – 1.084 
rs3734431 7397.70 7397.29 0.522 0.695 1.070 0.873 – 1.312 
rs3756980 7382.39 7377.02 0.0205 0.146 1.178 1.027 – 1.350 
rs6904769 7412.24 7405.32 0.00852 0.0909 0.783 0.649 – 0.945 
rs6922246 7385.15 7375.98 0.00246 0.0459 0.797 0.685 – 0.926 
rs13191212 7338.89 7336.61 0.131 0.280 0.861 0.706 – 1.050 
rs13219629 7396.63 7392.00 0.0314 0.146 1.202 1.020 – 1.417 
rs16883343 7320.80 7320.25 0.458 0.667 1.050 0.923 – 1.195 
rs384505 7427.11 7423.90 0.0732 0.195 1.109 0.990 – 1.243 
rs1802061 7427.11 7426.74 0.543 0.695 0.928 0.727 – 1.185 
rs17608022 7427.11 7427.03 0.777 0.833 1.024 0.862 – 1.216 
 
FDR: false discovery rate; HR: hazard ratio; CI: confidence interval 
Cox proportional hazard multiple regression analysis of the combined SANAD and 
Glasgow cohorts shows that 1 SNP (rs6922246, FDR = 0.0459, HR = 0.797, 95% CI 
0.685 – 0.926) is significantly associated with time to 12-month remission. The KM 
curve for rs6922246 is shown below.  
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Figure 5.6. KM curve for rs6922246 (SANAD & Glasgow combined) 
 
Figure 4.6 is a Kaplan-Meir survival plot for rs6922246 in the combined SANAD and 
Glasgow cohorts. Patients with the mutant allele (2) are show to have a higher degree of 
seizure remission when compared with the heterozygous (1) and wild (0) genotypes. 
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Chapter 6: Discussion 
The ultimate goal of AED therapy is seizure freedom without adverse drug effects. 
Currently, over 30% of patients treated with several AEDs fail to become seizure-free and 
appear to be pharmacoresistant to the current available drugs (4). The patients that 
comprise the pharmacoresistant group have, by the nature of their epilepsy, been trialled 
on multiple AEDs with many efforts to titrate each drug to their maximum tolerated dose. 
Many of these efforts are attempted in vain, and commensurate with such polytherapy are 
often numerable side-effects that render the patient’s health and quality of life impacted 
upon. Therefore, markers that could differentiate between AED responders, and those that 
are pharmacoresistant, could potentially guide clinicians in predicting which patients 
initiated on AED therapy would be better responders than others. 
A GWAS was undertaken on the SANAD cohort of newly-diagnosed epilepsy patients 
whose results were meta-analysed with the AUS cohort. The primary outcome in this 
analysis was 1-year remission of seizures during any stage of follow-up with a minimum 
period of follow-up of 1 year. The results showed that SNP rs622902 (meta p-value = 
1.47×10
-7
) within the GSTA4 gene was most strongly associated with 1-year remission of 
seizures (unpublished data). As a consequence, this study sought to further investigate the 
role of GSTA4 in epilepsy by genotyping 17 SNPs within the GSTA4 gene that tagged for 
48 SNPs representing variation across the entire gene region. Analysis was carried out on 
SANAD and Glasgow DNA held at the University of Liverpool, which comprised 541 
and 390 patients, respectively. Genotype data was combined with known clinical data and 
the following clinical covariates:  
- Age 
- Sex 
- Epilepsy type (generalised, partial or unclassified) 
- Treatment (sodium valproate or gabapentin vs. neither) 
- EEG (normal, non-specific, not done) 
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- Number of pre-treatment seizures (2, 3, 4, 5, >5) 
An interesting observation from these covariates is the inclusion of gabapentin with 
sodium valproate. Original univariate logistic regression of the SANAD dataset illustrated 
that gabapentin was associated with a different outcome when compared with other 
antiepileptic drug – not that it was shown to be associated with a better outcome. This 
difference is also the reason as to why sodium valproate is included, as this was 
associated with a significantly different outcome compared with the other AEDs. The 
SANAD study showed that gabapentin was associated with a very poor outcome, whereas 
valproate was associated with a good outcome (10, 11). As such, both gabapentin and 
valproate were needed to be adjusted for in the genetic analysis.  
A binary logistic regression model was fitted for categorical ‘yes/no’ remission and Cox 
proportional hazards multivariate regression analysis for time to 12-month remission.  
Three SNPs were significantly associated with remission (binary outcome, yes/no) during 
follow-up in the SANAD cohort: rs6904769 (FDR = 0.0353), rs6922246 (FDR = 0.0109) 
and rs384505 (FDR = 0.0483). rs6904769 is an intronic C>T SNP found in the intra-
exonic gene region and is not found in LD with any known functional SNP. Its 
mechanism in the role of seizure remission cannot, therefore, be deduced. Both 
rs6922246 and rs384505 are downstream of the GSTA4 gene in the 3’ region and are G>T 
and G>A SNPs, respectively. Similarly, neither of these SNPs is in LD with any known 
functional variant. Whilst no mechanisms for these polymorphisms can be deduced, 
intronic and downstream 3’ SNPs may alter transcription factor binding and/or result in 
the reduced stability of mRNA respectively, with the possible subsequent alteration of the 
gene product. Altered GSTA4 protein may have several consequences, which include 
altered AED metabolism, or a role in the altered metabolism of the toxic lipid 
peroxidation product, 4-HNE. Although all three SNPs were significant in the SANAD 
cohort, replication in the Glasgow dataset failed. Combination of the two cohorts for 
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greater statistical power led to rs6922246 (FDR = 0.0459) being the only SNP associated 
with this phenotype. 
Two SNPs were significantly associated with time to 12-month remission: rs6904769 
(FDR = 0.0491) and rs6922246 (FDR = 0.00380). These associations were again seen in 
the SANAD dataset only, with failure of replication in the Glasgow cohort. In combining 
the two populations for greater statistical power, only one of the statistical associations 
held – rs6922246 (FDR = 0.0459).  
The fact that both rs6922246 and rs384505 are found in the downstream 3’ region of the 
GSTA4 gene may be of significance and would point towards a potential role of these 
variants in mRNA stability or susceptibility to degradation by micro-RNAs. How this 
then relates to the likelihood of achieving a remission from seizures is unclear.  
It is interesting to note that the association between remission of seizures following 
initiation of AED therapy and rs384505 was also seen in the GWAS conducted on the 
AUS cohort, and was the rationale for this SNP being included into our SNP selection. 
Whilst the rs384505 SNP did not show a significant association after combining the 
SANAD and Glasgow cohorts, replication was seen in the SANAD dataset. It is therefore 
reasonable to suggest that rs384505 may have a role in the remission of epilepsy, though 
further analysis is required. 
The original GWAS meta-analysis showed the most significant association with 1-year 
remission phenotype at the rs622902 loci. In our findings, this SNP did not show any 
statistical association in either outcome, even though genotyping was carried out on a 
subset of the same SANAD cohort. However, in the GWAS, significance at the loci of 
rs622902 may have simply represented significant polymorphic variation at the GSTA4 
region, which we have replicated, albeit in different SNPs. It is therefore reasonable to 
suggest that the findings in this study are more robust, given the denser genotyping 
conducted at this specific genomic region only.  
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In all of the statistical analyses conducted in this study, it appears that the greatest 
association between seizure remission is seen with rs6922246. Significant associations in 
the SANAD cohort were seen in both statistical models, and whilst replication was not 
seen in the Glasgow dataset, the associations held for the combined cohorts. This suggests 
that there may be a significant role for rs6922246 in newly-diagnosed epilepsy, and it is 
therefore a strong candidate for further validation.  
There are several hypotheses as to why the associations were not replicated in the 
Glasgow cohort. As stated, the Glasgow patients were representative of a discrete 
geographical area whose GSTA4 SNP variation may be different from the more extensive 
nation-wide population that was the SANAD cohort. A further issue exists in the 
diagnostic process of epilepsy; unlike most diseases that utilise GWAS, epilepsy is a 
diagnosis based upon clinical acumen with no definitive biochemical test. Therefore, in 
order to truly compare both cohorts, one must consider the possibility of variation in the 
clinical diagnosis of the condition between these groups, which could have significant 
effects on the results of a genome-wide association study. Combined, these limitations 
could substantially influence the results obtained in a GWAS analysis. 
SNP rs4147616 is a missense SNP and was, therefore, one of the force inclusion SNPs in 
the original list, though with MAF = 0.0069. However, analysis of the genotype data 
showed that there was a technical fault with the primers, as all reported genotypes were 
identical – this also resulted in the failure of Hardy-Weinberg equilibrium. Give missense 
SNPs are thought to be the most likely polymorphisms to result in a functional variant, it 
is disappointing that the genotype data was not available for our outcome analysis.   
The neighbouring gene upstream of GSTA4 is the intestinal cell kinase (ICK) gene. ICK is 
a protein found in the crypts of the intestinal villi and is responsible for cellular 
proliferation and differentiation (104). Thus, polymorphisms within ICK may result in the 
altered expression of channels in the intestine that are responsible for drug transport. 
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Interestingly, gabapentin is absorbed solely form the proximal small intestine and is 
excreted by the kidneys unaltered (105). With GSTA4 and ICK being in close genomic 
proximity, it may be that SNPs in these genes are in linkage disequilibrium – that is, the 
SNPs flagged in the GWAS may represent association with ICK  instead of GSTA4. 
Therefore, it is not unreasonable to suspect that polymorphic variation in ICK may alter 
the transport of gabapentin and afford some explanation to the results obtained in the 
earlier analysis.  
It is thought that genetic variability between individuals plays at least a part in 
determining whether patients are drug responders, or whether they are pharmacoresistant 
to therapy (98). GSTA4 is a ubiquitous enzyme that belongs to the glutathione-
conjugating super-family of enzymes. These enzymes, and in particular GSTA4, have 
been shown to be responsible for the metabolism of toxic by-products that are produced 
by lipid peroxidation reactions, namely the metabolite 4-HNE (92). In abnormal tissues 
that are subject to high cellular stress, 4-HNE is found in greater levels, and may be used 
as a biomarker for cellular stress (92, 93). This may be the case in epileptogenic tissue 
and may explain why GSTA4 has a role in epilepsy. Further, AEDs may lead to an 
increase 4-HNE concentration that, in abnormal epileptogenic tissue, may exacerbate 
seizures and result in pharmacoresistance. Upregulation of GSTA4 in tissues containing 
high 4-HNE concentrations may contribute to increased local metabolism of AEDs and 
thus compound pharmacoresistance in these patients.  
Unfortunately, there are no published studies that have explored the link between GSTA4 
and epilepsy. Associations between epilepsy and/or AEDs and other classes of GST have 
been shown (81, 95-97) although replication of these data and analysis in other 
independent cohorts is required. The association between these SNPs and remission from 
seizures is, therefore, novel, and necessitates further exploration in order to determine 
their functional significance and whether this association holds in the wider epilepsy 
population.  
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6.1. Limitations 
Clinical data obtained from the SANAD cohort that was used in this study was not 
originally intended for the use in the analyses of pharmacogenetic studies. Clinical report 
forms that were used to record clinical details were therefore not ideally designed for this 
purpose. Nevertheless, data was collected prospectively and is, therefore, assumed to be 
of high quality and free from bias. Data that was obtained from the Glasgow cohort was 
retrospectively collected from the hospital records. Given that no proforma was used, any 
details required could be obtained from the comprehensive patient notes, as outlined 
previously.  
It is not known which baseline clinical characteristics truly affect the outcome of the 
phenotypes studied, and therefore which should be adjusted for as clinical covariates in 
the statistical analyses. In this study, only those characteristics that were shown to be 
statistically significant in the original SANAD dataset were included, which may not have 
been appropriate for the Glasgow cohort and indeed may not be truly representative of the 
population. Neurological deficit was one of the covariates included in the original 
SANAD GWAS analysis, and indeed had one of the most significant p-values (p = 
0.001). Data regarding neurological deficit was, however, not available for the Glasgow 
cohort and could therefore not be included in this study. It is reasonable to believe that 
patients in whom neurological deficit is found may have more severe epilepsy than those 
without, and are therefore more likely to be pharmacoresistant to AEDs.  
It is known that certain AEDs are superior to others in controlling specific types of 
seizure/epilepsy from trials such as SANAD. In this study, AED therapy was grouped 
into sodium valproate or gabapentin vs. any other and were not analysed individually. 
Stratified analysis of each AED needs to be carried out in order to better appreciate the 
role of each medication in our outcome measure. The choice of AED may also have 
compounded the results, as many hospitals/epileptologists have preferential medications 
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they use that may vary from another epilepsy centre. This would be less influential on the 
SANAD cohort, though it may influence the results obtained from the Glasgow patients. 
Whilst the patients used in these studies represent the largest known genetic database of 
patients with newly-diagnosed epilepsy, the sample sizes may be insufficient to draw 
population-wide conclusions into these polymorphisms. The sample size may also be 
restricted further by the notorious difficulty in making an accurate diagnosis of epilepsy 
as described earlier – it is certainly not unreasonable to assume that a minority of 
individuals have, at least in part, an incorrect diagnosis, or have been initiated on a 
medication that is not entirely appropriate for their epilepsy type. Given these factors are 
clinician-dependant, they may be more pronounced in the Glasgow cohort and partly 
explain the lack of association seen in this patient group. 
Given little is known about which characteristics do affect our outcome of interest, it is 
difficult to know which should be recorded and included in any future research. Further 
testing of covariates in other studies, or meta-analyses of published works regarding 
which baseline characteristics show significance in epilepsy outcome, could elaborate on 
this issue and aid in future association studies.  
 
6.2. Summary of results 
Sixteen SNPs (one discarded owing to probable technical issues/failure of Hardy-
Weinberg equilibrium) that tagged for variation across the GSTA4 gene region were 
tested for associations between the remission of seizures (yes/no) and the time to 12-
month remission of seizures after adjusting for the six clinical covariate outlined above. 
Remission of epilepsy was statistically associated with SNPs rs6904769 and rs6922246 in 
the SANAD cohort. Of these, rs6922246 was the only SNP whose association held after 
combining the SANAD and Glasgow datasets for greater statistical power.  
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Time to 12-month remission of seizures was significantly associated with SNPs 
rs6904769, rs6922246 and rs384505 in the SANAD cohort. In combining the two 
datasets, this association held for rs6922246 only. It is therefore reasonable to conclude 
that there may be a link between remission of epilepsy, time to 12-month remission of 
epilepsy, and rs6922246 in particular, though further work to explore this role is required.  
 
6.3. Study Impact 
This study sought to determine the role of GSTA4 in newly-diagnosed epilepsy patients 
initiated on AED therapy. Via the selection of tagging SNPs representing variation across 
the GSTA4 genomic region, and the genotype analysis of these SNPs by TaqMan q-PCR 
and Sequenom MALDI-TOF MS analysis, it has been shown that rs6922246 is associated 
with both remission of epilepsy and time to 12-month remission of epilepsy in our patient 
cohorts. Further, two other SNPs showed association; rs6904769 and rs384505 in the 
SANAD cohort for both outcomes of interest. Validation of these results is an 
independent cohort is required to explore this link further.  
 
6.4. Future work 
Since the NCBI was consulted in order to produce our list of SNPs within the GSTA4 
gene, there has been publication of a missense SNP with MAF = 0.0011 (rs45551133). 
Whilst the MAF of this SNP is below the original cut-off value of 5%, this SNP is of 
potential functional significance and therefore analysis for any association and our 
outcomes of interest would be a possible avenue for future work.  
Sequencing of the GSTA4 gene region in patients with epilepsy and healthy control 
subjects could potentially show novel variants between the groups with subsequent 
analysis regarding their function. This type of genetic analysis has been shown to be 
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successful in several clinical studies, and was used by Lupski et al (106) to identify 
polymorphisms in a small cohort diagnosed with the neuro-genetic disorder, Charcot-
Marie-Tooth. The participants in the study were routinely tested for common variants 
known to be associated with Charcot-marrie-Tooth, the results of which were negative. 
Following further gene sequencing as outlined, novel SNPs were discovered. Similarly, 
Ley et al (107) used a sequencing method to discover 8 new genetic variants in a patient 
with acute myeloid leukaemia that were not present in matched, health control tissue.  
Functional studies investigating how GSTA4 relates to epilepsy and AEDs could be 
another research area of interest. rs6922246 is a SNP located within the downstream 3’ 
region of the gene, having possible effect on mRNA stability and protein transcription. In 
order to investigate this, methods that involve the expression of the mutant and wild 
GSTA4 protein using E.coli plasmids could be utilised. In the initial phase, the level of 
GSTA4 protein could be compared such that any mRNA instability in the mutant type 
would result in a decrease of protein expression. E.coli plasmids containing transfected 
GSTA4 protein are available commercially via LGC standards (http://www.lgcstandards-
atcc.org/LGCAdvancedCatalogueSearch/ProductDescription/tabid/1068/Default.aspx?AT
CCNum=MGC-9318&Template=mgcHumanClones).   
Given the significant role of GSTA4 in the metabolism of 4-HNE and subsequent 
importance in the mechanisms of cellular stress (92), its upregulation in epileptogenic 
tissue and consequent increased metabolism of AEDs is also another area of potential 
interest. In the first instance, non-mutant GSTA4 protein could be used in order to assess 
the metabolising capabilities of certain AEDs in order to ascertain to what extent GSTA4 
may metabolise these xenobiotics. If successful, studies could then be conducted in order 
to investigate how the rs6922246 SNP variant affects metabolism.  
Finally, and with regard to the SNP findings of this study, our results require validation in 
a large, independent cohort that should ideally be prospective in nature in order to evade 
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confounding factors and bias, and be designed with a pharmacogenetic ideation in mind. 
It would be useful to have further information, as outlined in section 5.1, on those clinical 
covariates known to influence seizure outcome though this information is not yet 
available. Validation in an independent cohort is, for the time, difficult, as both the 
SANAD and Glasgow cohorts are the largest known datasets of newly-diagnosed 
epilepsy patients for which access to DNA is available, and thus replication is, for the 
moment, not possible. The SANAD-II clinical trial is in the phases of development, and 
later pharmacogenetic analysis in this cohort may be possible in order to attempt to 
replicate our findings, and would provide another large population in which to conduct 
further pharmacogenetic analysis into newly-diagnosed epilepsy.  
 
6.5. Conclusion 
The pharmacoresistant phenotype is seen in approximately 30% of the epilepsy 
population and represents a significant global health issue. Despite the advent of newer 
antiepileptic agents, there has been no significant move forward in the clinical 
management of these patients (3, 4). Genetic variation between individuals is thought to 
contribute to this phenotype, and it was the purpose of this study to investigate the role of 
SNPs in the GSTA4 gene with outcome measurements being remission of seizures 
(yes/no) and time to 12-month remission. 
The remission of seizures was associated with rs6904769 and rs6922246 in the SANAD 
cohort, although after combining both cohorts for statistical power association was only 
seen in rs6922246.  
Time to 12-month remission was associated with rs6904769, rs6922246 and rs384505 in 
the SANAD cohort. After combining both datasets, only rs6922246 was significantly 
associated with this outcome.  
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In conclusion, we have found that, particularly, rs6922246 is associated with both of our 
outcome measures. Validation of our findings in an independent cohort is necessary to 
confirm the role of this SNP variant in the GSTA4 gene, though the limitations of this 
have been described. Future research into GSTA4 and its genetic variants are necessitated 
to further our knowledge of its role in epilepsy, with the ultimate aim being the 
development of a gene marker that could be used in clinical practise to predict the 
response patients may have to AED therapy. 
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